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Preface 
We are delighted to share with you the 2014 Annual Report from the European Cystic Fibrosis Society 
Patient Registry (ECFSPR). This report contains epidemiological data from national cystic fibrosis (CF) 
registries and individual CF centres throughout Europe and neighbouring countries. It is the eighth official 
report, and includes demographic and clinical data of 35,582 consenting CF patients from 26 countries.  
In January 2014, we introduced a new software platform: ECFSTracker. The transition to this new software 
has taken some time and this has delayed the production of the 2011 and 2012 reports. Reports for the 
2011 and 2012 data will be published in electronic format in the coming months.  
The publication of the 2014 report 20 months after the end of the data-collection year, reflects our 
development plan to publish the annual reports within 18 months of the close of the calendar year, ideally 
in time for the ECFS Conference in June. Moreover, it is our objective to encourage the use of the 
encounter-based component in ECFSTracker. We hope that, over time, the ability to enter encounter-
based data, thereby capturing clinical interaction in real time, may be of value to CF clinicians as well as 
ensure a faster and more efficient collection of data. More information about the ECFSTracker software 
you will find on the webpage www.ecfs.eu/ecfspr-software.  
The primary goal of the ECFSPR is to allow comparison between CF clinical outcomes across Europe. The 
analysis presented in this report has been carried out by the ECFSPR statistician using all the raw data, in 
anonymised form, entered by the participating countries. Analysing the raw data allows comparison 
between different countries’ data, something not possible using the individual countries’ own annual 
reports. As a result of merging this data, analysis of some countries as presented in the ECSFPR report may 
differ from the data published in their national annual registry report. Differences can originate from 
patient inclusion criteria, different definitions used for disease complications and employment of different 
reference values. Further details on how this occurs and how this is dealt with can be found in the report 
and in the List of ECFSPR Variables and Definitions in Appendix 2 (page 122). Currently the ECFSPR is 
working with other international CF registries to harmonise the collection, presentation and interpretation 
of CF registry data worldwide. An example of this work is the standardisation of lung function prediction 
equations; it has been agreed that the Global Lung Function Initiative (GLI) equations should be used. In 
this report, for the first time, we present ECFSPR data on lung function based on the GLI equations. To 
allow comparison with previous annual reports, we also report lung function using the formerly used 
prediction equation, shown in Appendix 3 (page 126).  
Over the past few years we have seen continuous growth of the ECFSPR. This report contains information 
from 26 countries with a total of 70 centres using the direct-data entry function of the ECFSPR software. 
We expect that the number of countries participating in the ECFSPR will continue to increase. Managing 
the ECFSPR comes with a cost and we are deeply indebted to our sponsors whose unrestricted grants have 
helped support the running and expansion of the Registry.  
In addition to being the basis for this annual report, the ECFSPR data is used for research and other 
purposes to benefit people with CF, such as epidemiological research, assessing feasibility of clinical trials, 
and production of evidence needed by pharmaceutical companies in order to apply for approval of new 
treatments. Over the past five years, from 2011 to 2015, we have received 38 formal requests to use 
ECFSPR data. We are confident that the ECFSPR is evolving into a valuable resource for CF epidemiology  
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and health service research. We are currently finalising the development of a tool to benchmark centre 
and country results against meaningful standards, in collaboration with the ECFS Quality of Care Working 
Group. This benchmarking module will be integrated into ECFSTracker, and we expect to launch it in 
selected centres early in 2017.  
The management of the ECFSPR and the development of this report take a considerable amount of work. 
I would like to take this opportunity to thank the national registries and individual centres, as well as the 
country representatives for their participation in the ECFSPR, especially in dealing with the huge demands 
of data collection and uploading for the 2011 to 2014 years. I would also like to thank the ECFSPR staff that 
have worked so hard on the production of this report and the running of the Registry. In particular, Jacqui 
van Rens, the ECFSPR Executive Coordinator, who ensures that everything, from data collection and 
handling of research requests to the arrangements for the bi-annual European meetings, runs like clock-
work. I would like to thank the Service Desk, Alice Fox and Patrizia Iansa, for dealing with the many 
challenges associated with the increasing number of countries joining the ECFSPR. Alice and Patrizia have 
worked exceptionally hard in providing support on the ECFSTracker software to the participating countries 
with many different languages and multiple different hospital IT systems. Finally, many thanks to our 
statistician, Anna Zolin, for her careful and professional approach to the data analysis, an essential 
component of the Registry. Through the combined efforts of the ECFSPR staff and Executive Committee, 
in conjunction with the hard work of the members of the individual centres and countries that volunteer 
so much of their time, serial data from 2011 to 2014 has been uploaded to the ECFSPR in the past two 
years, a considerable accomplishment that has hugely improved the value of the Registry as an instrument 
for research and quality improvement. For this, we at the ECFSPR are extremely grateful.  
Finally, I would like to thank all the people with CF throughout Europe for their willingness to participate 
in the ECFSPR. Without them, this Registry would not exist. We hope that the Registry’s information is 
useful for people with CF, their families and caregivers and that it will lead to improved CF care 
throughout Europe. 
 
Sincerely, 
 
Edward F. McKone, MD, FRCPI 
ECFSPR Director 
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To the people with cystic fibrosis 
This report is about you and how cystic fibrosis (CF) affects you and other people all over Europe. The 
report is based on information collected by individual CF centres and the national CF registries that 
participate in the European Cystic Fibrosis Society Patient Registry (ECFSPR). We have tried to make the 
presentation of this data as clear as possible and hope that you will find the report interesting and easy to 
understand.  
We will continue publishing key-information of the ECFSPR Report in a separate At-a-Glance report, with 
relevant information for the people with CF and their families. Over the coming year, we will work on a 
more sophisticated electronic version of this report, as well as additional tools to increase patient 
awareness of the Registry, such as posters with information about the Registry for distribution in CF-clinics 
and increasing our presence on social media.  
If you have any suggestions on how we can improve the information or if something is unclear you are 
welcome to contact us. You can send an email to: ecfs-pr@uzleuven.be.  
For discussions about the results in your country we encourage you to contact your CF centre.  
More detailed information about the ECFSPR you will find on the patient-dedicated page of our website, 
www.ecfs.eu/projects/ecfs-patient-registry/information-about-ecfspr-cf-patients. 
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List of centres and national registries that provided 
the data 
List of individual centres and national registries that contributed to the ECFSPR.  
In Italics: new participants since the previous report with 2013 data;  
In large print: the name of the country representative in the ECFSPR Steering Group; 
Underlined: the name of the database manager for the national registry. 
 
Country Centre/National Registry name Contact 
Austria 12 individual centres:  
Thomas Frischer 
Andreas Pfleger (from 
October 2016) 
 
Medizinische Universität Graz, Universitätsklinik für 
Kinder- und Jugendheilkunde, Klinische Abteilung für 
Pädiatrische Pulmonologie und Allergologie und CF 
Zentrum für Kinder, Jugendliche und Erwachsene, Graz 
Ernst Eber 
Maria Wagenhofer 
 
Medizinische Universität Innsbruck, Departement für 
Kinder- und Jugendheilkunde, CF Zentrum für Kinder, 
Jugendliche und Erwachsene, Innsbruck 
Helmut Ellemunter 
Johannes Eder 
 
Klinikum Klagenfurt am Wörthersee, Abteilung für Kinder- 
und Jugendheilkunde, Pädiatrische  
Pulmologie/Allergologie, Klagenfurt  
Franz Hubert Wadlegger 
 
Kepler Universitätsklinikum, Kinder- und Jugendheilkunde, 
Abteilung Mucoviszidose, Linz 
Maria Bauer 
 
Kardinal Schwarzenberg’sches Krankenhaus, Abteiling für 
Kinder- und Jugendmedizin, Schwarzach 
Christoph Seelbach 
 
Landeskrankenhaus Steyr, Abteilung für Kinder- und 
Jugendheilkunde und Abteilung für Lungenheilkunde, 
Steyr 
Josef Emhofer 
Alexander Ebner 
 
Allgemeines Krankenhaus Wien, Universitätsklinik für 
Chirurgie, Klinische Abteilung für Thoraxchirurgie, Vienna 
Peter Jaksch 
Sabine Obermair Ramp 
 
Krankenhaus Hietzing, Abteilung für Atmungs- und 
Lungenerkrankungen, Vienna 
Ingrid Kaluza 
 
Universitätsklinik für Kinder- und Jugendheilkunde, 
Cystische Fibrose Ambulanz, Vienna 
Sabine Renner 
Brigitte Mersi 
 
Wilhelminenspital, Abteilung für Kinder- und 
Jugendheilkunde mit Ambulanz, Vienna 
Thomas Frischer 
Kerstin Tiringer              
 
Klinikum Wels-Grieskirchen, Abteilung für Kinder- und 
Jugendheilkunde, Wels 
Elisabeth Steiner  
Vera Bauer 
Beatrix Wintersteiger 
Nadine Raffler 
 
Klinikum Wels-Grieskirchen, Abteilung für 
Lungenkrankheiten, Wels 
Helmut Feizelmeier 
Belgium Belgian Cystic Fibrosis Registry 
Muriel Thomas 
Simeon Wanyama 
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Country Centre/National Registry name Contact  
Czech Republic Cystic Fibrosis Registry of the Czech Republic 
Pavel Drevinek  
Milan Macek  
Alena Bilkova 
Marek Turnovec 
Denmark Cystic Fibrosis Registry of Denmark 
Hanne Vebert Olesen  
Tania Pressler 
France Registre Français de la Mucoviscidose 
Virginie Colomb 
Lydie Lemonnier 
Greece 3 individual centres: Elpis Hatziagorou 
 Aghia Sophia Children's Hospital, CF Centre, Athens 
Athanasios Kaditis 
Ioanna Loukou 
Argyri Petrocheilou 
Fotini Tsiakalou 
 
Sismanoglio General Hospital of Attica,  
Adult Cystic Fibrosis Unit, Athens 
Filia Diamantea 
Kostas Kotsifas 
 
Aristotle University of Thessaloniki, Hippokration General 
Hospital, Cystic Fibrosis Centre, Thessaloniki 
John Tsanakas  
Elpis Hatziagorou  
Maria Fotoulaki 
John Kioumis 
Hungary Cystic Fibrosis Registry of Hungary 
Rita Ujhelyi  
Géza Marsal  
Attila Hornyák 
Ireland Cystic Fibrosis Registry of Ireland 
Godfrey Fletcher 
Abaigeal Jackson 
Shijun Zhou 
Israel Cystic Fibrosis Registry of Israel Meir Mei-Zahav 
Italy Cystic Fibrosis Registry of Italy 
Rita Padoan 
Gianluca Ferrari  
Patrizia Iansa 
Marco Salvatore 
Latvia 1 individual centre: Karina Mahlina 
 
Rīga Stradinš University, Children’s Clinical University 
Hospital, Department of Pneumology, Riga 
Vija Švabe  
Karina Mahlina 
Lithuania 1 individual centre: Kęstutis Malakauskas 
 
Hospital of Lithuanian University of Health Sciences, Kaunas 
Clinics, Adult Cystic Fibrosis Centre, Kaunas 
Kęstutis Malakauskas 
Republic of 
Macedonia 
1 individual centre: Stojka Fustik 
 
University Children’s Hospital, Centre for Cystic Fibrosis, 
Skopje 
Stojka Fustik 
Republic of 
Moldova 
Cystic Fibrosis Registry of Moldova Svetlana Sciucca 
Netherlands Dutch Cystic Fibrosis Registry Vincent Gulmans 
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Country Centre/National Registry name Contact  
Portugal Cystic Fibrosis Registry of Portugal Luísa Pereira 
Romania 1 individual centre: Simona Mosescu 
 
Clinical Children’s Hospital, Grigore Alexandrescu, Bukarest, 
Romania 
Simona Mosescu 
Russian 
Federation 
Cystic Fibrosis Registry of the Russian Federation 
Nataliya Kashirskaya 
Alexander Chernyak  
Elena Amelina 
Stanislav Krasovskiy 
Elena Kondrtyeva 
Anna Voronkova 
Serbia 1 individual centre: Milan Rodic 
 
National Centre for Cystic Fibrosis, Mother and Child Health 
Institute of Serbia "Dr Vukan Cupic", Belgrade 
Milan Rodic 
Slovakia Cystic Fibrosis Registry of Slovakia 
Hana Kayserova  
Mariá Drugdova 
Slovenia 2 individual centres: Uroš Krivec 
 University Clinic of Pulmonary and Allergic Diseases, Golnik 
Matjaž Fležar  
Andraz Jakelj 
 
University Children`s Hospital, Pulmonary Department, 
Ljubljana 
Uroš Krivec 
Ana Kotnik Pirs 
Spain 15 individual centres: Carlos Vazquez-Cordero 
 
Hospital de Sabadell, Corporació Sanitària Parc Taulí, Clinica 
Pediátrica, Unitat Clinica de Fibrosis Quística, Barcelona 
Xavier Domingo Miró 
 
Hospital Sant Joan de Déu, Unitat de Pneumologia 
Pediátrica i  Fibrosi Quística, Barcelona 
Jordi Costa i Colomer 
 
Hospital Vall d'Hebron, Unidad Fibrosis  Quística e 
Neumologia Pediátrica, Barcelona 
Silvia Gartner 
 
Hospital Universitario La Princesa, Neumologia Adultos, 
Madrid 
Rosa María Girón 
 
Hospital Niño Jesús, Sección de Neumologia 
Pediátrica/Unidad de Fibrosis Quística, Madrid 
Jose R. Villa Asensi 
 
Hospital Universitario de Ramón y Cajal, Unidad de Fibrosis 
Quística, Madrid 
Adelaida Lamas Ferreiro 
 Hospital 12 de Octubre, Unidad de Fibrosis Quística, Madrid Gloria Garcia Hernandez 
 
Hospital Regionale Universitario de Málaga, Unidad Fibrosis 
Quística Adultos, Málaga 
Casilda Olveira Fuster  
Gabriel Maria Olveira Fuster 
Nuria Porras Pèrez 
 
Hospital Regional Universitario de Málaga, Unidad de 
Fibrosis Quística Pediátrica, Málaga 
Francisco Javier Perez-Frias 
Estela Perez-Ruiz 
Pilar Caro-Aguilera 
 
Hospital Universitario Virgen de la Arrixaca, Unidad de 
Fibrosis Quística, Murcia 
Pedro Mondéjar-López 
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Country Centre/National Registry name Contact  
 Hospital Universitario Virgen del Rocío, Unidad de Fibrosis 
Quística, Sevilla    
Isabel Delgado Pecellín 
Esther Quintana Gallego 
 
Hospital Clinico Universitario de Valencia, Unidad de 
Fibrosis Quística Pediátrica, Valencia  
Amparo Escribano 
Montaner Silvia Castillo 
 
Hospital Universitario La Fe, Unidad de Trasplante 
Pulmonar y Fibrosis Quística, Valencia 
Amparo Solé Jover 
Carmen Inés Perez Munoz 
 
Hospital Universitario de Cruces, Unidad de Fibrosis 
Quística, Bizkaya 
Carlos Vazquez Cordero 
 
Hospital Universitario Miguel Servet, Unidad de 
Neumología Pediátrica y Fibrosis Quística, Zaragoza 
Carlos Martín de Vicente 
Sweden Cystic Fibrosis Registry of Sweden Isabelle de Monestrol 
Anders Lindblad 
Switzerland 14 individual centres: Andreas Jung 
 
Kantonsspital Aarau AG, Klinik für Kinder und Jugendliche, 
Abteilung pädiatrische Pneumologie, Allergologie und 
Immunologie, Klinik für Pneumologie und Schlafmedizin, 
Aarau  
Dominik Müller-Suter  
Sarosh Irani 
 
Lindenhofspital Bern, Praxis für Pneumologie "Quartier 
Bleu", Bern 
Reta Fischer 
Carlo Mordasini 
 
Universitätsklinik für Kinderheilkunde, Zentrum für 
Cystische Fibrose und Pulmonologie, Inselspital, Bern 
Carmen Casaulta 
Philipp Latzin 
 Hôpital Cantonal Fribourg, Pädiatrie, Fribourg 
Denise Herzog 
Johannes Wildhaber 
 
Hôpitaux Universitaires de Genève, Département de 
l’enfant et de l’adolescent, Unité de Pneumologie 
Pédiatrique, Genève 
Constance Barrazzone 
Anne Mornand 
 
Hôpitaux Universitaires de Genève, Département des 
Spécialités de Medicine, Service de Pneumologie, 
Consultation de Muco-viscidose Adulte, Genève 
Paola Gasche 
Jérôme Plojoux 
 
Centre Hospitalier Universitaire Vaudois (CHUV), 
Départment Médico-Chirurgical de Pédiatrie, Pneumologie 
Pédiatrique et Mucoviscidose, Lausanne 
Gaudenz Hafen 
Macha Rochat 
 
Centre Hospitalier Universitaire Vaudois (CHUV),  
Policlinique Médicale Universitaire, Départment de 
Médecine, Consultation Adulte de Mucoviscidose, 
Lausanne 
Laurent Nicod 
Marie Hofer 
 
Luzerner Kantonsspital, Zentrum für Zystische Fibrose für 
Kinder und Erwachsene, Abteilungen  für Pneumologie, 
pädiatrische Pneumologie und pädiatrische 
Gastroenterologie,  Luzern 
Bernhard Schwizer 
Nicolas Regamey  
Johannes Spalinger 
 
Hôpital de Morges, Consultation de Mucoviscidose Adulte, 
Morges 
Alain Sauty 
Marie Hofer 
 
Ostschweizer Kinderspital, Pädiatrische Pneumologie und 
CF-Zentrum, St. Gallen 
Jürg Barben 
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Country Centre/National Registry name Contact  
 Kantonspital St Gallen, Klinik für Pneumologie und 
Schlafmedizin, Spezialsprechstunde für Adulte Cystische 
Fibrose, St. Gallen 
Martin Brutsche 
Rebekka Kleiner 
 
Universitäts-Kinderspital Zürich, Abteilung für Pneumologie, 
Zürich 
Andreas Jung 
Romy Rodriguez 
Alexander Möller 
 
Universitätsspital Zürich, Klinik für Pneumologie, Adultes CF 
Zentrum, Zürich 
Christian Benden 
Thomas Kurowski 
Ukraine 1 individual centre: Halyna Makukh 
 
SI “Institute of Hereditary Pathology of Ukranian National 
Medical Academy”, Lviv 
Halyna Makukh 
Lyudmyla Bober 
United Kingdom UK Cystic Fibrosis Registry 
Rebecca Cosgriff 
Elaine Gunn 
Siobhán Carr 
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Introduction 
The European Cystic Fibrosis Society Patient Registry (ECFSPR) 
The ECFSPR collects demographic and clinical data of consenting cystic fibrosis (CF) patients from Europe 
and neighbouring countries. Data is collected using a common set of variables and definitions, and is sent 
to the ECFSPR in one of the following ways: 
 National CF registries (or individual centres with local databases) extract patient data from their 
own database and import the data into the ECFSPR software; 
 Individual centres enter patient data directly into the ECFSPR software. 
Collection of data at a local level must be approved by local data protection authorities in accordance with 
European data protection legislation. Data stored in the central database is anonymous, and only 
year/month of birth and randomised centre numbers are used as identifiers. Data is available for scientific 
purposes on application. All requests are reviewed by the ECFSPR Scientific Committee and, based on their 
recommendation, the country representatives in the Steering Group (composed of national represen-
tatives of the countries that contribute data to the ECFSPR) decide if the data request is approved or not; 
this decision is final.  Requests originating from the Industry are also reviewed by the ECFS Clinical Trials 
Network. All applications must meet the European and individual country data protection legislation 
regarding patient anonymity. 
For more information, please visit our website www.ecfs.eu/projects/ecfs-patient-registry/intro. 
General Considerations 
For the national registries, it is possible that some of their definitions and data coding do not fully 
correspond to those employed by the ECFSPR, either because some types of information are not collected, 
or are collected by the national registry using a different method. When the national registries upload their 
data they are also asked to state in a document whether their variables definitions meet those of the 
ECFSPR. Where major discrepancies between the definitions are present, those variables have been 
omitted from the annual report, and in the case of minor discrepancies a footnote has been added to the 
graphs and tables. For example, the ECFSPR collects information on the presence of chronic Pseudomonas 
aeruginosa infection according to the modified Leeds criteria and/or the presence of elevated 
Pseudomonas antibodies (see Appendix 2 on page 122). If a national registry collects such information as 
“at least one positive Pseudomonas aeruginosa culture this year”, this information would be too different 
from the ECFSPR definition of chronic Pseudomonas aeruginosa, and we would set this variable to 
“missing” for that particular country. If, instead, a country defines chronic Pseudomonas aeruginosa as 
“the presence of more than four positive cultures in 6 months”, the data of this variable would be included 
in the annual report since the definition is much closer to the ECFSPR definition. Where this is the case, a 
footnote has been added to the relevant tables and graphs. 
 
If a country does not collect a certain variable (or if it is completely different from the ECFSPR definitions 
as described above), we have omitted that country from the relevant graphs in the report. The same 
applies for countries where the information for a variable is missing for more than 10% of the patients. All 
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data, however, is presented in the tables. The number of missing values is important for the interpretation 
of the results, since it is impossible to know if a patient with a missing value for a given complication has 
this complication or not, which makes the given frequencies less accurate. For example, in a country where 
7% of the patients have liver disease but 20% of patients have unknown/missing information on liver 
disease, the true frequency of liver disease can be anything between 7 and 27%. 
 
You will find some differences between the findings of the national registries’ own reports and the ECFSPR 
report. This is because some variable values are recoded or computed in different ways. For example, 
some national registries compute the age at the annual visit and consider 16 years as the cut-off for adult 
age. The ECFSPR computes the age at FEV1/height/weight measurement and the age at follow-up (the end 
of the year) and considers 18 years as the cut-off for adult age. Since clinical outcomes do not change very 
much over a 12 month period, we do not consider this to be a serious obstacle to interpretation. Another 
example: for lung function values such as FEV1 the raw data values, reported in litres, are not informative 
unless they are expressed in relation to the age, sex and height of the patient. We therefore needed to 
transform the raw values into new variables in order to compare lung function between patients and 
countries. We used common reference populations for all data when calculating the values as a percentage 
of predicted from the raw data. Slightly different values can be obtained when using another reference 
population on the same raw data. It is important to use a common method of calculation when comparing 
different countries, just as the national registries choose a common method of calculation when they 
compare the individual centres in that country. 
 
Glossary and Abbreviations 
Country codes:  
 
AT:  Austria 
BE:  Belgium 
CH:  Switzerland 
CZ:  Czech Republic 
DK:  Denmark 
ES:  Spain 
FR:  France 
GR:  Greece 
HU:  Hungary 
IE:  Ireland 
IL:  Israel 
IT:  Italy 
LT:  Lithuania 
 
 
 
 
  
LV:  Latvia 
MD:  Republic of Moldova 
MK:  Republic of Macedonia 
NL:  The Netherlands 
PT:  Portugal 
RO:  Romania 
RS:  Serbia 
RU:  Russian Federation 
SE:  Sweden 
SI:  Slovenia 
SK:  Slovak Republic 
UA:  Ukraine 
UK:  United Kingdom 
  
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
14 
 
  
Explanation of terms: 
ABPA: allergic bronchopulmonary aspergillosis, an allergic reaction to the mould Aspergillus. 
BMI: body mass index (weight (kg)/(height (m)2). 
Bronchodilator: medication that relaxes the muscles of the airways, used also for asthma. 
CFRD: CF-related diabetes. 
CFTR: CF transmembrane conductance regulator, is a protein at the cell surface that controls the salt and water 
balance across a cell. The gene that causes CF is the blueprint for the CFTR protein. Everyone has two copies of the 
gene for CFTR, but to be born with CF, both CFTR genes must be affected by a CF-causing mutation.  
FEV1: forced expiratory volume in one second (lung function parameter). 
FEV1%: the FEV1 as a percentage of the average value for healthy people of the same age, height and sex. 
Haemoptysis: coughing up blood. This happens frequently in small amounts in CF, so the complication we asked for 
here is major bleeding (more than 250 ml). 
Homozygous: CF is caused by mutations of the CFTR gene, one on each allele. One is inherited from the mother and 
one from the father. If both mutations are the same, the person is said to be homozygous for this mutation. 
Heterozygous: CF is caused by mutations of the CFTR gene, one on each allele. One is inherited from the mother and 
one from the father. If these are two different mutations, the person is considered to be heterozygous. 
Max: maximum. It is the highest value. 
Mean: it is the average value of a set of measurements. For example, if the mean age at diagnosis is 3 years, it means 
that, on average, the patients are diagnosed when they are 3 years old. 
Meconium ileus: congenital obstruction of the gut with thick, sticky faeces. 
Median: the value that separates the set of measurements in two halves, so that 50% of measurements are below 
the median value and the other 50% of measurements are above the median value. For example, if median age at 
diagnosis is 5 months, it means that half of the patients are diagnosed before 5 months of age, and the other half of 
the patients are diagnosed after 5 months of age. 
Min: minimum. It is the lowest value. 
N: the number of patients in a group for whom the information is not missing. 
N miss: number of missing values. It is the number of patients for whom the information was missing. 
NaCl: sodium chloride. Here: inhaled hypertonic saline. 
Pancreatic insufficiency: the absence of pancreatic enzymes in the gut leading to malnutrition if not treated 
(pancreatic insufficiency is therefore defined as the use of pancreatic enzyme supplementation). 
25th Pctl: 25th percentile, also called first quartile. It is the value that separates the set of measurements in two parts, 
so that one quarter (25%) of the measurements is below it and the other three quarters are above it. For example, if 
the 25th percentile for age at diagnosis is 1 month, it means that a quarter of the patients are diagnosed before 1 
month of age, and the other three quarters are diagnosed after 1 month of age. 
75th Pctl: 75th percentile, also called third quartile. It is the value that separates the set of measurements in two parts, 
so that three quarters (75%) are below it and the other quarter is above it. For example, if the 75th percentile for age 
at diagnosis is 3 years, it means that three quarters of the patients are diagnosed before 3 years, the other quarter 
are diagnosed after 3 years. 
Pneumothorax: collapsed lung, in CF usually because of severe lung damage. 
Quartiles: The 25th Percentile, the median (the 50th Percentile) and the 75th percentile are collectively called quartiles, 
because they divide the set of measurements into quarters. 
rhDNase: ribosomal human DNase – marketed as Pulmozyme®. 
Z-score: it indicates how far a value is from the mean value of a reference population (see Appendix 1 for details). 
Negative z-scores mean that the value is below the mean of values in the reference population, whereas positive z-
scores mean that the value is above the mean. For example, a z-score for weight of -2 means that the weight is 2 
standard deviations below the mean of subjects of the same age and sex of the reference population. For example, 
if the z-score for BMI of a 10 years old boy is -2, it means that the BMI for that boy is 2 standard deviations below the 
mean BMI of 10 years old boys of the reference population. 
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
15 
 
  
Summary of data report 
Outcome  Females Males Total 
Patients registered in the 
ECFSPR 
n 
(%) 
16856 
(47.37) 
18726 
(52.63) 
35582* 
Age at follow-up (in years, 
patients alive on 
31/12/2014) 
mean 
median 
20.0 
18.0 
20.9 
19.3 
20.5 
18.6 
Patients ≥ 18 years (patients 
alive on 31/12/2014) 
% 50.1 53.3 51.8 
Age at diagnosis** mean (years) 
median (months) 
4.1 
3.6 
4.0 
3.6 
4.1 
3.6 
Patients with at least one 
F508del allele** 
% 81.7 81.5 81.6 
Patients living with lung 
transplant** 
n 
(%) 
841 
(5.5) 
860 
(5.1) 
1701 
(5.3) 
Patients living with liver 
transplant** 
n 
(%) 
60 
(0.4) 
109 
(0.6) 
169 
(0.5) 
Patients deceased in 2014*** n 
(%) 
203 
(1.3) 
183 
(1.0) 
386 
(1.1) 
Age at death*** mean (years) 
median (years) 
27.8 
25.0 
29.6 
29.0 
28.7 
27.0 
 
* For demographic purposes Belgian 2013 data (N=1,186) has been included in this total. 
** Only patients seen during the year are presented. Belgian 2013 data (N=1,153) is not included. The total number 
of patients presented is 32,514. 
** Only patients seen during the year are presented. Belgian 2013 data (N=1,153) is not included. For the United 
Kingdom, all seen patients with confirmed diagnosis of CF are included (N=10,580). The total number of patients 
presented is 33,664. 
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Data report 
1. Demographics 
Figure 1.1 Map of countries that contributed to the ECFSPR in 2014. 
 
 
 
 
Countries that contributed 2014 data are in blue. 
Germany, who will send these data at the end of 2016, is in grey. 
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Table 1.1 Number of patients in 2014, by country. 
Country Patients registered, 
not lost to follow-up 
Patients seen Estimated coverage 2014 
Austria 712 687 90% 
Belgium* 1186 1153 >90%1 
Czech Republic* 599 599 >95% 
Denmark* 488 459 >95% 
France* 6369 6369 90% 
Greece** 517 507 90% 
Hungary* 557 557 >90% 
Ireland* 1218 942 >90% 
Israel** 666 547 95% 
Italy* 4981 4980 >90% 
Latvia 38 38 >90% 
Lithuania 12 12 20%2 
Rep of Macedonia 109 100 >90% 
Rep of Moldova* 61 61 68-76% 
The Netherlands* 1378 1378 98% 
Portugal** 295 258 85% 
Romania 44 40 10%3 
Russian Federation* 2122 2121 63% 
Serbia 169 154 >90% 
Slovak Republic** 290 241 >90% 
Slovenia 97 84 >95% 
Spain 1538 1481 50% 
Sweden* 626 626 >90% 
Switzerland 782 736 >80% 
Ukraine 147 107 15-18% 
United Kingdom* 10581 9430 99%4 
Total 35582 33667  
 
* Countries with an established national CF registry. 
** These countries have a national registry, but use the direct data-entry function of ECFSTracker. 
1 Data are from 2013 and presented for demographic purposes. The 2014 data could not be delivered in time due 
to the introduction of a new data-collection and validation software. 
2 Coverage is 100% for adults and 0% for children. 
3 Coverage is 0% for adults and 100% for children. 
4  The total number for UK is two patients less than the 2014 UK annual report due to the removal of CF diagnosis.  
 
The column “Patients registered, not lost to follow-up” shows the patients that attend centres, and in-
cludes patients that have not been seen during the year but are known to be alive that year.  
The column “patients seen” presents the patients who have a recorded clinic attendance during the year.  
The column “Estimated coverage 2014” shows the estimated percentage of CF patients living in that 
country who are included in the national registries/national data collections as reported by the country. 
For some countries one individual centre may include almost all patients, e.g. Latvia and Serbia. 
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In all subsequent tables and graphs, the data referred to is for 2014, except for Belgium, for which 2013 
data was used. The Belgian 2013 data is shown for demographic purposes and presented only in the 
demographic section. 
Figure 1.2 Number of patients registered in the ECFSPR in 2014, by country. 
 
 
 
Each vertical bar shows the number of registered patients living in that country in 2014. Please refer to 
table 1.1 for the coverage in each country.  
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Figure 1.3 Age at follow-up distribution. Patients registered alive on 31/12/2014. 
 
 
Each blue vertical bar represents the number of patients of that age alive in 2014. The cumulative 
percentage (the dark blue line) describes how many patients (as a percentage) are below a certain age 
(e.g. 50% of the patients are younger than 18.6 years old). 
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Figure 1.4 Age at follow-up distribution by sex. Patients registered, alive on 31/12/2014. 
 
 
The pyramid shows the percentage of patients of different ages as horizontal bars. The blue side of the 
pyramid shows, for males, how many patients (as a percentage) are a certain age, the red side shows the 
same for females. The lower percentage of patients at the bottom of the pyramid is due to the fact that 
some patients have not yet been diagnosed (mean age at diagnosis is 4.08 years, see table 2.1).  
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Table 1.2 Proportion of adults (≥18 years) and children (<18 years), by country. Patients registered, 
alive on 31/12/2014. 
Country Children (<18 years) 
number (%) 
Adults (≥18 years) 
number (%) 
Austria 376 330 
 (53.26) (46.74) 
Belgium 508 673 
 (43.01) (56.99) 
Czech Republic 327 262 
 (55.52) (44.48) 
Denmark 186 297 
 (38.51) (61.49) 
France 3018 3281 
 (47.91) (52.09) 
Greece 259 255 
 (50.39) (49.61) 
Hungary 304 243 
 (55.58) (44.42) 
Ireland 554 644 
 (46.24) (53.76) 
Israel 279 382 
 (42.21) (57.79) 
Italy 2211 2720 
 (44.84) (55.16) 
Latvia 27 11 
 (71.05) (28.95) 
Lithuania 0 12 
 (0) (100) 
Rep of Macedonia 81 28 
 (74.31) (25.69) 
Rep of Moldova 46 13 
 (77.97) (22.03) 
The Netherlands 597 769 
 (43.70) (56.30) 
Portugal 164 131 
 (55.59) (44.41) 
Romania 42 1 
 (97.67) (2.33) 
Russian Federation 1472 611 
 (70.67) (29.33) 
Serbia 117 50 
 (70.06) (29.94) 
Slovak Republic 130 158 
 (45.14) (54.86) 
Slovenia 61 36 
 (62.89) (37.11) 
Spain 882 644 
 (57.80) (42.20) 
Sweden 234 387 
 (37.68) (62.32) 
Switzerland 392 388 
 (50.26) (49.74) 
Ukraine 127 19 
 (86.99) (13.01) 
United Kingdom 4572 5880 
 (43.74) (56.26) 
Total 16966 18225 
 (48.21) (51.79) 
   Belgium: 2013 data. 
   Lithuania: coverage is 100% for adults and 0% for children. 
   Romania: coverage is 0% for adults and 100% for children. 
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Figure 1.5  Proportion of adults (≥18 years) and children (<18 years). Patients registered, alive on 
31/12/2014. 
 
 
Note: Belgium: 2013 data. 
 Lithuania: coverage is 100% for adults and 0% for children. 
Romania: coverage is 0% for adults and 100% for children. 
 
This graph shows the percentage of patients in each country who are adults (dark blue) or children (light 
blue). The percentage of adult patients varies considerably between the different countries. One of the 
reasons is the way the patients are included: for some countries only a few individual centres sent data to 
the ECFSPR, and the proportion of children and adults may reflect the proportion of paediatric and adult 
centres in that country that participate in the ECFSPR. Please refer to table 1.1 for national coverage.  
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Table 1.3 Age at follow-up: descriptive statistics, by country and overall. Patients registered, alive 
on 31/12/2014. 
Country N Mean 
 
(average 
age) 
Min 
 
(age of the 
youngest 
patient) 
25th pctl 
 
(25% of the 
patients are 
younger 
than this 
age) 
Median 
 
(half the 
patients are 
younger 
than this 
age) 
75th pctl 
 
(75% of the 
patients are 
younger 
than this 
age) 
Austria 706 18.2 0.2 8.9 16.9 26.0 
Belgium 1181 22.6 0.2 11.9 20.5 31.5 
Czech Republic 589 17.8 0.2 8.3 16.5 25.2 
Denmark 483 23.7 0.1 12.5 22.0 34.6 
France 6299 20.7 0.1 9.8 18.9 29.3 
Greece 514 19.1 0.4 9.6 17.8 26.2 
Hungary 547 17.4 0.2 9.8 16.1 23.4 
Ireland 1198 20.7 0.4 10.3 19.5 29.7 
Israel 661 22.0 0.1 11.7 20.8 30.2 
Italy 4931 22.3 0.0 10.5 20.1 32.6 
Latvia 38 13.9 0.8 7.1 13.6 19.4 
Lithuania 12 24.6 19.1 21.7 24.2 27.6 
Rep of Macedonia 109 13.0 0.9 6.7 11.6 18.0 
Rep of Moldova 59 11.6 0.9 4.9 9.0 15.8 
The Netherlands 1366 22.4 0.1 11.5 20.7 31.3 
Portugal 295 18.9 0.3 9.3 16.6 26.5 
Romania 43 8.0 0.5 3.0 7.5 11.5 
Russian Federation 2083 12.8 0.0 4.7 10.2 19.9 
Serbia 167 14.2 0.3 6.5 12.5 20.1 
Slovak Republic 288 20.0 0.2 10.8 19.7 26.0 
Slovenia 97 15.9 0.1 5.9 14.4 21.4 
Spain 1526 17.9 0.0 7.6 15.5 26.3 
Sweden 621 24.1 0.5 11.7 22.4 34.0 
Switzerland 780 19.1 0.0 8.0 17.9 26.4 
Ukraine 146 10.2 0.2 4.9 10.2 14.0 
United Kingdom 10452 21.6 0.0 10.0 20.2 30.5 
Total 35191 20.5 0.0 9.4 18.6 29.2 
 
  Note: Belgium: 2013 data. 
 Lithuania: coverage is 100% for adults and 0% for children. 
 Romania: coverage is 0% for adults and 100% for children. 
 
This table shows the descriptive statistics for age at follow-up of the patients by country and overall. Only 
registered patients who were alive on December 31st 2014 are included.  
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Figure 1.6 Age at follow-up: box-plot, by country and overall. Patients registered, alive on 31/12/2014. 
 
Note: Belgium: 2013 data. 
 Lithuania: coverage is 100% for adults and 0% for children. 
Romania: coverage is 0% for adults and 100% for children. 
This box-plot is a graphic representation of the age detailed in table 1.3. For each country the dash 
(black line crossing the blue box) is the median, the black dot is the mean and the whiskers (vertical 
lines with a T-shaped end) are the minimum and the maximum. The following figure explains how 
to read the box. 
 
 
 
Note:   This is an example of how to read a boxplot. The numbers used in this figure are not real and 
do not refer to figure 1.6. 
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Figure 1.7 Sex distribution, by country and overall. Patients registered, alive on 31/12/2014. 
 
Sex distribution of all patients. Overall (see “Total”), in the ECFSPR there are more male than female 
patients, which could reflect higher mortality in female CF patients. The proportion is not uniform across 
the different countries. 
Figure 1.8 Sex distribution, by country and overall. Patients registered alive on 31/12/2014 and 
aged 18 years or more. 
 
Note: Romania has only one adult patient and is excluded from the graph. 
Sex distribution for adult patients. The total proportion of females in the adult group is similar to the 
proportion of females in the whole population. 
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2. Diagnosis 
From here onwards, only patients seen during the year are presented and Belgian 2013 data (N=1,153) is 
not included. The information on diagnosis and on all the other sections for people with CF registered in 
Belgium are reported in the ECFSPR Annual Report 2013.  
 
Table 2.1 Age at diagnosis (in years): descriptive statistics, by country and overall. All patients seen 
in 2014. 
Country N N miss Mean 
 
(average 
age at 
diagnosis) 
Min  
 
(lowest 
age at 
diagnosis) 
25th pctl 
 
(25 % of the 
patients 
were 
diagnosed 
before this 
age) 
Median 
 
(half the 
patients 
were 
diagnosed 
before 
this age) 
75th pctl 
 
(75% of the 
patients 
were 
diagnosed 
before this 
age) 
Max 
 
(highest 
age at 
diagnosis) 
Austria 624 63 2.34 0.0 0.10 0.20 0.87 61.00 
Czech Republic 599 0 2.91 0.0 0.10 0.40 2.50 53.90 
Denmark 459 0 2.25 0.0 0.17 0.50 2.00 37.00 
France 6047 322 4.33 0.0 0.10 0.20 3.00 77.00 
Greece 494 13 2.64 0.0 0.25 0.50 2.00 53.00 
Hungary 428 129 2.65 0.0 0.00 1.00 3.00 42.00 
Ireland 942 0 2.54 0.0 0.06 0.28 1.63 75.83 
Israel 540 7 5.31 0.0 0.11 0.60 5.54 65.00 
Italy 4679 301 5.60 0.0 0.11 0.36 5.00 72.97 
Latvia 37 1 3.49 0.0 0.50 1.00 5.00 14.00 
Lithuania 12 0 10.58 1.0 4.50 10.5 15.00 24.00 
Rep of Macedonia 100 0 1.62 0.0 0.20 0.30 0.85 16.20 
Rep of Moldova 61 0 3.25 0.0 0.30 0.50 2.00 35.00 
The Netherlands 1293 85 3.81 0.0 0.10 0.50 3.00 63.00 
Portugal 251 7 6.47 0.0 0.30 1.70 8.00 58.00 
Romania 40 0 1.58 0.2 0.20 0.30 0.50 16.50 
Russian Federation 2116 5 3.55 0.0 0.19 0.72 4.20 58.95 
Serbia 149 5 2.99 0.1 0.30 0.90 4.00 32.50 
Slovak Republic 200 41 6.62 0.0 0.16 1.00 9.00 72.00 
Slovenia 81 3 1.82 0.0 0.15 0.45 1.75 16.50 
Spain 1435 46 4.01 0.0 0.15 0.50 2.90 65.00 
Sweden 614 12 4.06 0.0 0.19 0.79 3.04 70.61 
Switzerland 633 103 2.86 0.0 0.10 0.50 2.00 55.00 
Ukraine 107 0 3.43 0.1 0.50 1.80 5.00 27.40 
United Kingdom 9298 132 3.87 0.0 0.06 0.25 2.00 79.30 
Total 31239 1275 4.08 0.0 0.10 0.33 2.97 79.30 
 
Note:  For Hungary, Slovak Republic and Switzerland the information on age at diagnosis is missing for more than 
10% of the patients. 
 
This table shows the descriptive statistics for age at diagnosis by country and overall. For prenatal 
diagnoses (children diagnosed before birth), the age at diagnosis has been set to 0. 
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
27 
 
  
Figure 2.1 Age at diagnosis (in years): box-plot, by country and overall. All patients seen in 2014. 
 
                               //                                                                                                                                  // 
 
Note: For Hungary, Slovak Republic and Switzerland the information on age at diagnosis is missing for more 
than 10% of the patients. 
 
This box-plot is a graphic representation of age at diagnosis as detailed in table 2.1. For each country 
the dash (black line crossing the blue box) is the median, the black dot is the mean and the whiskers 
(vertical lines with a T-shaped end) are the minimum and the maximum. Please note that the vertical 
axis is interrupted to emphasise the change of scale in the upper part of the graph. The figure on the 
next page explains how to read the box. 
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                                                              //             // 
 
 
 
Note:  This is an example of how to read a boxplot. The numbers used in this figure are not real and do not 
refer  to figure 2.1.  
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Figure 2.2 Proportion of patients diagnosed at age 1 month or younger, younger than 1 year and older 
than 18 years, by country and overall. All patients seen in 2014. 
 
 
Note: For Hungary, Slovak Republic and Switzerland the information on age at diagnosis is missing for more 
than 10% of the patients. 
 
 
This graphs shows age at diagnosis in subgroups. The vertical bars represent how many patients (as a 
percentage) were diagnosed within the first month of life (grey), within the first year of life (light green), 
and after 18 years of age (dark green). Note that the diagnoses included in the sub-group for within 1 
month are also part of the diagnoses in the sub-group for within the first year, and that diagnoses between 
1 year and 18 years are not shown on the graph, therefore the bars do not sum to 100%. 
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Figure 2.3 Proportion of patients who underwent neonatal screening, by country and overall. Patients 
5 years old or younger seen in 2014.  
 
 
Note: For Czech Republic, Israel and Italy the information on neonatal screening is missing for more than 10% of 
the patients. 
Czech Republic: positive answers (“neonatal screening performed”) are reported when neonatal screening 
is one of the factors that led to CF diagnosis. 
France: neonatal screening is recorded only if it is part of the diagnosis. 
United Kingdom: new born screening has been introduced for all babies born across the UK since 2007. The 
data above indicate that the CF diagnosis was suggested by neonatal screening. 
 
 
This graph shows the percentage of patients of 5 years old or younger in 2014 who were screened at birth, 
(see country specific notes above). Dark green horizontal bars represent newborn screening “performed”, 
light green ones “not performed”. This graph shows that in some countries there is no newborn screening 
and that in others, in the five years previous to 2014, almost all the CF patients underwent newborn 
screening. In total, almost 75% of all children of 5 years old or younger registered in the ECFSPR in 2014 
underwent newborn screening, but this estimate reflects the fact that not all the countries perform 
newborn screening. 
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Figure 2.4 Patients with meconium ileus, by country and overall. Patients aged 10 years or younger.  
 
 
Note: For Hungary, Israel and Switzerland the information on meconium ileus is missing for more than 10% of 
the patients. 
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Figure 2.5 Patients with meconium ileus, by country and overall. Patients aged 11 years or older. 
 
 
Note: For Hungary, Lithuania, Switzerland, The Netherlands and United Kingdom the information on meconium 
ileus is missing for more than 10% of the patients. 
 
 
These two graphs show the prevalence of meconium ileus (operated or not) at birth in two age groups: 0 
to 10 years (fig 2.4) and 11 years or older (fig 2.5). Overall, the proportion of child patients (≤10 years) with 
meconium ileus is higher compared to the older age group (>10 years). This difference is not due to an 
increase in the prevalence of meconium ileus in the younger generations, but could be due to the fact that 
some older patients with meconium ileus have died, and are therefore not present in the current data 
collection (which refers to patients seen in 2014). The graphs also show that the frequency of reported 
meconium ileus varies between countries.  
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3. Genetics 
Cystic fibrosis is caused by mutations of the CFTR gene; one on each allele. One is inherited from the 
mother and one from the father. If both mutations are the same, the person is said to be homozygous for 
this mutation. If these are two different mutations, the person is considered to be heterozygous. 
 
We supplied the countries with a list of the 1600 most common mutations based on the Cystic Fibrosis 
Mutation database (CFTR1). If the patient had a mutation that was not present in the database, the country 
had the possibility to enter the name of the mutation as free text. During the data cleaning process the 
genotypes not on our list were checked for obvious misspellings or alternative names and, if identified as 
a known mutation, renamed. Although there are different naming conventions for mutations, we use the 
original mutation name (legacy name) in this report, since more than 90% of the mutations in the database 
use this nomenclature. 
 
If DNA analysis to look for CFTR mutations was never carried out, we asked the countries to report “Not 
done” in the genotype field. If DNA analysis was done but only one or no mutations were found, we asked 
the countries to write “Unknown” for the un-identified mutations. Please note that there are differences 
from country to country in how DNA testing is carried out; some countries use standard kits that test only 
a limited number of common mutations (e.g. 28), and other countries perform DNA analyses of the whole 
gene until the mutation is identified. 
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Table 3.1 Proportion of patients with DNA analysis and the result of this, by country and overall. All 
patients seen in 2014.  
Country N Genotyping  Among genotyping done 
not done 
 
number (%) 
done 
 
number (%) 
unknown 
 
number (%) 
two mutations 
identified 
number (%) 
at least one mutation 
unknown 
number (%) 
Austria 687 2 (0.29) 685 (99.71) 0 (0) 603 (88.03) 82 (11.97) 
Czech Republic 599 1 (0.17) 598 (99.83) 0 (0) 580 (96.99) 18 (3.01) 
Denmark 459 0 (0) 459 (100) 0 (0) 457 (99.56) 2 (0.44) 
France 6369 0 (0) 6369 (100) 0 (0) 6042 (94.87) 327 (5.13) 
Greece 507 0 (0) 507 (100) 0 (0) 444 (87.57) 63 (12.43) 
Hungary 557 17 (3.05) 539 (96.77) 1 (0.18) 375 (69.57) 164 (30.43) 
Ireland 942 0 (0) 942 (100) 0 (0) 903 (95.86) 39 (4.14) 
Israel 547 1 (0.18) 546 (99.82) 0 (0) 440 (80.59) 106 (19.41) 
Italy 4980 24 (0.48) 4956 (99.52) 0 (0) 4463 (90.05) 493 (9.95) 
Latvia 38 0 (0) 38 (100) 0 (0) 27 (71.05) 11 (28.95) 
Lithuania 12 0 (0) 12 (100) 0 (0) 11 (91.67) 1 (8.33) 
Rep of Macedonia 100 1 (1.00) 99 (99.00) 0 (0) 96 (96.97) 3 (3.03) 
Rep of Moldova 61 0 (0) 61 (100) 0 (0) 43 (70.49) 18 (29.51) 
The Netherlands 1378 15 (1.09) 1363 (98.91) 0 (0) 1342 (98.46) 21 (1.54) 
Portugal 258 2 (0.78) 256 (99.22) 0 (0) 251 (98.05) 5 (1.95) 
Romania 40 0 (0) 40 (100) 0 (0) 20 (50.00) 20 (50.00) 
Russian Federation 2121 234 (11.03) 1887 (88.97) 0 (0) 1302 (69.00) 585 (31.00) 
Serbia 154 7 (4.55) 147 (95.45) 0 (0) 115 (78.23) 32 (21.77) 
Slovak Republic 241 0 (0) 241 (100) 0 (0) 197 (81.74) 44 (18.26) 
Slovenia 84 2 (2.38) 82 (97.62) 0 (0) 78 (95.12) 4 (4.88) 
Spain 1481 3 (0.20) 1478 (99.80) 0 (0) 1290 (87.28) 188 (12.72) 
Sweden 626 0 (0) 626 (100) 0 (0) 617 (98.56) 9 (1.44) 
Switzerland 736 7 (0.95) 728 (98.91) 1 (0.14) 699 (96.02) 29 (3.98) 
Ukraine 107 0 (0) 107 (100) 0 (0) 96 (89.72) 11 (10.28) 
United Kingdom 9430 <5 9411 (99.8) 18 (0.19) 8600 (91.38) 811 (8.62) 
Total 32514 317 (0.97) 32177 (98.96) 20 (0.06) 29091 (90.41) 3086 (9.59) 
 
Note: For United Kingdom, when the number of patients is less than 5 the information is suppressed. 
 
The table shows how many patients underwent DNA analysis to identify the CFTR mutations (column 
“genotyping done”) and, for those patients, how many patients had both mutations identified (column 
“two mutations identified”) and for how many one or both mutations remained unidentified (column “at 
least one mutation unknown”). 
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Figure 3.1 Proportion of identified mutations, by country and overall. Only patients with DNA analysis. 
 
 
 
This graph shows the percentage of mutations that are not identified (unknown in light pink) after DNA 
analysis, by country and overall. One “allele” means one of the two CFTR genes. The number of non-
identified alleles varies greatly from country to country; this is partly due to the different approaches to 
DNA testing. Overall, more than 5% of mutations remain unidentified after DNA analysis, leaving 9.59% of 
the patients with at least one mutation unidentified. 
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Figure 3.2 Prevalence of F508del homozygous and heterozygous patients, by country and overall. All 
patients seen in 2014. 
 
 
F508del is the name of the most commonly occurring CFTR mutation in the world. Patients who carry two 
F508del mutations are often described as having “classic CF”, but other combinations of mutations may 
cause the same degree of disease. We have grouped the patients in F508del homozygous (have two 
F508del mutations), F508del heterozygous (have one F508del mutation and another mutation, different 
from F508del), and patients without F508del mutations. Only patients for whom the genotype is known 
have been included in this graph. “Unknown” mutations have been classified as “other”, since F508del is 
included in all genotyping kits and would have been identified. Please note that the genotype grouping in 
this graph does not reflect the severity of the disease in the countries. 
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Table 3.2  Allelic frequencies of the 15 most common mutations in the ECFSPR database. 
Mutation name Number of alleles Percentage among 
tested 
Country with highest allele 
frequency 
F508del 39412 61.24 Denmark (82.24%) 
G542X 1783 2.77 Rep of Macedonia (6.06%) 
N1303K 1341 2.08 Italy (5.62%) 
G551D 909 1.41 Ireland (8.70%) 
W1282X 762 1.18 Israel (23.08%) 
R117H 708 1.1 United Kingdom (2.33%) 
2789+5G->A 610 0.95 Italy (2.88%) 
1717-1G->A 580 0.9 Switzerland (2.75%) 
3849+10kbC->T 527 0.82 Lithuania (16.67%) 
621+1G->T 464 0.72 Greece (6.21%) 
R553X 461 0.72 Lithuania (8.33%) 
CFTRdele2,3 413 0.64 Czech Republic (6.10%) 
2183AA->G 364 0.57 Italy (2.00%) 
R1162X 364 0.57 Slovenia (4.88%) 
D1152H 361 0.56 Israel (4.95%) 
 
This table presents the allele frequency of the 15 most commonly occurring mutations found in the ECFSPR 
database. The last column indicates in which country the particular mutation is most frequent. F508del is 
by far the most frequent mutation. Additionally, since F508del is included in all genetic screening tests, 
this is also the mutation with the highest detection rate.  
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Figure 3.3 Geographical distribution of mutation F508del. 
 
 
 
 
Although this mutation is the most common in all countries, the allele frequency still varies from 24.27% 
in Israel to 82.24% in Denmark. 
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Figure 3.4 Geographical distribution of mutation G542X. 
 
 
 
 
 
This mutation is very rarely found in Scandinavia (0.76% in Denmark and 0.72% in Sweden, 0.0% in Latvia 
and Lithuania).  
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Figure 3.5 Geographical distribution of mutation N1303K. 
 
 
 
 
This mutation is most frequent in Italy (5.62%) and other countries in Southern Europe and in Eastern 
Europe, but rare in Northern Europe. 
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Figure 3.6 Geographical distribution of mutation G551D. 
 
 
 
Note: Israel: G551D was not in the mutation panel for 2014, therefore the prevalence is unknown. 
 
 
This mutation is most frequent in Ireland (8.70%), whereas it is very rare in Southern Europe (less than 
0.5%). 
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Figure 3.7 Geographical distribution of mutation W1282X. 
 
 
 
 
This mutation, of Middle-Eastern origin, is by far most frequent in Israel (23.08%) with a very high allele 
frequency in Ashkenazi Jews.  
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4. Lung function 
FEV1 is measured in litres but it is normally expressed as a percentage of the expected value (FEV1%). The 
expected value is computed from healthy individuals of the same sex, height and age and is termed the 
reference population.  
In this report we used, for the first time, the Global Lung Function Initiative equations described by Quanjer 
PH et al. (see Appendix 1, page 120, for full reference). This is the global reference for spirometry and it 
has been agreed, as part of the CF global harmonisation project, that this is the best way to present lung 
function. We will continue to use these equations from now on in our reports. In Appendix 3 (page 126) 
we have also included the outcomes based on the reference populations and equations described by Wang 
et al. for children, and Hankinson et al. for adults (see Appendix 1, page 120, for full reference).   
A FEV1% of 100 means that the lung function measurement is equal to the mean lung function measure-
ment of people of the same age, sex and height of the healthy reference population. 
Spirometry, the test that measures FEV1, requires a certain amount of coordination, and usually cannot be 
performed until a person with CF is about six years of age. We have therefore computed FEV1% values only 
for patients aged 6 years or older. 
We asked the countries to report the best FEV1 recorded throughout the year (according to the FEV1% 
computed at the CF centres) to the ECFSPR. A few national registries do not record the best value, but 
other FEV1 values that may not be the patient’s best that year, so we added a footnote to the tables and 
graphs describing which FEV1 was reported from those countries. Research has shown that when 
comparing groups of patients, the difference between the best FEV1% and a random value from the same 
year can be up to 4.3% points1. This finding should be taken into consideration when comparing the results. 
Likewise, as lung function in CF deteriorates with age, differences in FEV1 may reflect that the CF 
population of a country is older. 
We excluded patients from the analyses on FEV1 who have had one or more lung transplants, since their 
lung function does not reflect the severity of their CF lung disease. 
 
 
 
 
 
 
 
 
 
1 Wanyama et al, JCF 2014; 9, S1:428  
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Table 4.1  FEV1% of predicted: descriptive statistics by country. Patients aged 6-17 years who have 
never had a lung transplant. 
Country N N Miss Mean 
 
(average 
FEV1%) 
Min 25th pctl 
 
(25% of 
patients have 
FEV1% below 
this value) 
Median 
 
(50% of 
patients have 
FEV1% below 
this value) 
75th pctl 
 
(75% of 
patients have 
FEV1% below 
this value) 
Max 
Austria 252 3 89.6 26.0 78.4 92.3 102.5 129.9 
Czech Republic 201 13 85.7 24.6 77.4 88.2 96.2 128.8 
Denmark 140 0 95.2 37.3 88.1 98.3 105.0 130.3 
France 2029 103 88.3 16.0 77.4 90.3 101.0 171.0 
Greece 130 2 96.4 22.2 87.5 99.0 107.8 147.3 
Hungary 207 16 75.6 16.1 65.8 78.6 89.5 127.2 
Ireland 358 12 87.5 25.1 77.2 89.5 99.8 148.6 
Israel 173 5 91.5 31.9 82.5 94.8 102.1 126.2 
Italy 1057 27 92.8 24.9 81.2 94.5 106.7 148.9 
Latvia 15 0 91.3 27 83.7 92.9 107.8 123.3 
Rep of Macedonia 51 2 92.9 31.2 82.5 94.5 108.7 128.0 
Rep of Moldova 22 2 73.6 22.8 62.5 77.1 90.1 105.7 
The Netherlands 410 10 87.4 28.8 75.7 88.1 100.6 131.9 
Portugal 103 8 81.1 23.4 66.7 84.4 98.4 126.1 
Romania 23 0 90.3 41.4 80.4 95.0 104.2 114.5 
Russian Federation 534 244 83.5 15.3 70.0 85.1 98.3 158.9 
Serbia 74 0 79.6 26.1 67.1 83.7 94.9 119.6 
Slovak Republic 76 0 83.5 24.8 76.0 87.2 95.2 121.2 
Slovenia 35 0 75.9 27.7 59.9 80.0 91.1 116.5 
Spain 517 18 89.1 28.3 77.6 91.5 102.2 137.1 
Sweden1 163 6 87.9 30.6 76.6 89.9 99.7 128.4 
Switzerland 226 4 88.4 28.1 77.4 89.2 100.5 128.7 
Ukraine 60 1 87.2 21.2 75.0 93.5 99.5 126.4 
United Kingdom2 2106 745 85.8 19.7 76.3 87.5 97.4 144.9 
 
1  Sweden reports FEV1 collected at the time of the annual review. 
2 United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
 
This table shows some descriptive statistics for FEV1 in children, expressed as % of predicted. Note that 
patients who have had a lung transplant and children below 6 years of age have been excluded from the 
analyses. 
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Figure 4.1 FEV1% of predicted: box-plot, by country and overall. Patients aged 6-17 years who have 
never had a lung transplant. 
 
 
Note:  Sweden reports FEV1 collected at the time of the annual review. 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
 
 
This box-plot is a graphic representation of the FEV1 in children, expressed as % of predicted, detailed in 
table 4.1. For each country the dash (black line crossing the blue box) is the median, the black dot is the 
mean and the whiskers (vertical lines with a T-shaped end) are the minimum and the maximum.   
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Table 4.2 FEV1% of predicted: descriptive statistics by country. Patients aged 18 years or older who have 
never had a lung transplant. 
Country N N Miss Mean 
 
(average 
FEV1%) 
Min 25th pctl 
 
(25% of 
patients have 
FEV1% below 
this value) 
Median 
 
(50% of 
patients have 
FEV1% below 
this value) 
75th pctl 
 
(75% of 
patients have 
FEV1% below 
this value) 
Max 
Austria 265 2 73.3 14.0 56.3 75.1 90.8 132.4 
Czech Republic 132 77 65.8 18.8 48.2 67.4 84.6 115.3 
Denmark 222 0 71.8 17.5 54.3 73.2 90.6 122.7 
France 2508 62 64.9 11.7 45.7 64.8 83.5 135.2 
Greece 185 0 64.3 15.9 41.6 64.3 87.0 117.1 
Hungary 162 7 69.6 15.0 50.5 71.1 94.6 108.6 
Ireland 329 19 64.0 15.3 44.9 63.9 80.3 125.0 
Israel 265 0 69.5 22.2 54.1 70.7 83.2 127.2 
Italy 1890 52 71.9 10.8 52.1 72.4 92.7 143.9 
Latvia <10 0 42.1 19.9 20.8 38.0 49.8 86.3 
Lithuania 12 0 59.2 21.4 29.2 60.7 85.5 92.9 
Rep of Macedonia 22 0 76.1 42.0 65.2 73.7 89.5 121.5 
Rep of Moldova 13 0 55.0 19.4 36.5 54.6 69.9 99.3 
The Netherlands 638 24 66.1 10.8 49.0 65.9 83.3 122.7 
Portugal 82 1 67.4 24.6 48.3 70.0 82.2 135.3 
Russian Federation 398 134 58.2 14.3 37.2 57.3 76.4 140.5 
Serbia 38 0 56.6 15.2 43.6 56.9 65.2 107.3 
Slovak Republic 112 0 68.5 17.2 49.6 72.0 87.3 119.1 
Slovenia 22 0 60.7 23.5 43.2 62.6 77.1 101.0 
Spain 474 13 66.7 20.0 48.4 67.1 83.6 122.2 
Sweden1 309 10 73.4 19.5 57.8 75.0 88.6 124.8 
Switzerland 303 0 63.9 12.8 46.9 62.1 81.8 115.0 
Ukraine 10 1 64.3 24.1 43.1 68.1 85.9 91.4 
United Kingdom2 3533 1261 68.0 13.0 49.8 68.7 85.7 154.6 
 
1  Sweden reports FEV1 collected at the time of the annual review. 
2  United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
Note: Romania has one adult patient and is excluded from the table. 
 
This table shows some descriptive statistics for FEV1 in adults, expressed as % of predicted. Note that 
patients who have had a lung transplant have been excluded from the analyses. 
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Figure 4.2 FEV1% of predicted: box-plot by country and overall. Patients aged 18 years or older who 
have never had a lung transplant. 
 
Note:  Sweden reports FEV1 collected at the time of the annual review. 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note:  Romania has one patient and is excluded from the graph. 
 
 
This box-plot is a graphic representation of the FEV1 in adults, expressed as % of predicted, detailed in 
table 4.2. For each country the dash (black line crossing the blue box) is the median, the black dot is the 
mean and the whiskers (vertical lines with a T-shaped end) are the minimum and the maximum.   
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Figure 4.3 Median FEV1% of predicted by age group and by country. Patients aged 6 years or older who 
have never had a lung transplant. 
 
 
Note: We excluded from the analyses those age groups with the number of patients <10.  
Note: Not all the countries reported the best FEV1 value of the year (see tables 4.1 and 4.2). 
 
 
This graph shows the median FEV1% (the value that separates the highest and lowest half of the patients) 
by age group. Each country is represented by a dot (in blue) and the overall estimate is in red. The general 
pattern shows that the FEV1% slowly decreases until the age of 30-34, and then levels out. The patients in 
the oldest age groups are patients that survived, and may therefore represent the patients with less 
disease severity. There is considerable variability between countries. 
 
Table 4.3 FEV1% of predicted: descriptive statistics by age group (patients aged 6 years or older) who 
have never had a lung transplant. 
Age at FEV1 
measurement  
N N Miss Mean 
 
Min 25th pctl 
 
Median 
 
75th pctl 
 
Max 
6-9 3089 503 94.7 18 85.3 96.3 105.6 158.9 
10-14 3681 434 86.4 23.4 75.9 88.1 98.5 171 
15-19 3575 466 78.7 15.2 64.9 81.5 93.8 154.6 
20-24 3190 416 71.4 12.5 54.5 73.2 89.5 143.9 
25-29 2474 351 65.7 10.8 46.9 66.2 83.8 143.1 
30-34 1784 231 62.7 13.1 44.2 61.1 79.7 134.2 
35-39 1181 155 62.6 11.7 43.7 60.9 80.4 129.7 
40-44 777 130 63.1 13.9 44.1 61.2 81.0 139.2 
45+ 1142 198 64.5 10.8 44.7 61.8 82.7 137.3 
Note: Not every country reported the best FEV1 value of the year (see tables 4.1 and 4.2). 
 
This table shows FEV1% by age group for the total data set. The median values reported in this table are 
shown as red dots in fig 4.3. 
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Figure 4.4 Quartiles of FEV1% of predicted by age group and by country. Patients aged 6 years or 
older and who have never had a lung transplant. 
The figures below show the FEV1% in different age groups, separately for each country. The dot shows the 
median, and the whiskers show the 25th and 75th percentiles (the median, the 25th percentile and the 75th 
percentile are collectively named “quartiles”). In blue are the quartiles for the country, in red are the 
pooled quartiles computed on all other countries (i.e. excluding that country). We did not compute 
quartiles where the number of patients is <10 in an age group, so there are no blue dots for those age 
groups (the number of patients in each age group is shown below the horizontal axis). We therefore 
excluded Latvia and Lithuania from the graphs because none of the age groups had more than 10 patients. 
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[figure 4.4 continued] 
Quartiles of FEV1%: Ireland Quartiles of FEV1%: Israel 
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[figure 4.4 continued] 
Quartiles of FEV1%: Slovak Republic Quartiles of FEV1%: Slovenia 
  
 
Quartiles of FEV1%: Spain 
 
Quartiles of FEV1%: Sweden1 
  
 
Quartles of FEV1%: Switzerland 
 
Quartiles of FEV1%: Ukraine 
  
 
Quartiles of FEV1%: United Kingdom2 
 
 
 
1 Sweden reports FEV1 collected at the time of the annual review. 
2 United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
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Figure 4.5 FEV1% of predicted according to severity group and age group, by country and overall.  
Patients aged 6-17 years who have never had a lung transplant. 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: For Lithuania coverage is 0% for children. 
 
 
Figures 4.5, 4.6 and 4.7 show the FEV1% by severity group, by country and overall. Patients with a FEV1% 
above 80% are generally considered to have mild lung disease, patients with FEV1% between 80% and 40% 
moderate lung disease, and patients with FEV1 below 40% severe lung disease. However, since a 10 year 
old child with a lung function of 50% has considerably worse lung disease than a 50 year old patient with 
the same FEV1%, and the age distribution is not the same in all countries, we have chosen to present 
children (fig 4.5) and adults (fig 4.6 and 4.7) separately.  
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Figure 4.6 FEV1% of predicted according to severity group and age group, by country and overall. 
Patients aged 18-29 years who have never had a lung transplant. 
 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: Romania has only one patient and is excluded from the graph. 
 
 
Figure 4.7 FEV1% of predicted according to severity group and age group, by country and overall. 
Patients aged 30 years or older who have never had a lung transplant. 
 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: Romania has only one patient and is excluded from the graph. 
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5. Microbiology 
We collect data on three chronic infections – Pseudomonas aeruginosa, Burkholderia cepacia complex 
species and Staphyloccocus aureus – as well as the occurrence of non-tuberculous mycobacteria (NTM) 
and Stenotrophomonas maltophilia.  
 
In the microbiology category discrepancies exist between the ECFSPR definitions and those of the 
national registries. The ECFSPR definition of chronic infection (see Appendix 2, page 122) is: 
 
Patient should be defined as chronically infected if he/she fulfils the criteria now or has done in 
recent years and the physician has no reason to think the status has changed: 
 
a. modified Leeds criteria, chronic infection: >50% of the sputum samples positive, collected 
during the last 12 months. At least 4 sputum samples during that period; 
 
b. and/or significantly raised bacteria-specific antibodies according to local laboratories.  
 
When minor differences exist the alternative definition is in a footnote; when differences are major, or if 
the variable is not collected at all, the variable has been set to missing for that country. 
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Table 5.1 Prevalence of chronic bacterial infection in all patients seen in 2014, by country. 
Country Chronic Pseudomonas 
aeruginosa 
number (%) 
Chronic Burkholderia cepacia 
complex species 
number (%) 
Chronic Staphylococcus aureus 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 10 494 183 9 653 25 13 301 373 
 (1.46) (71.91) (26.64) (1.31) (95.05) (3.64) (1.89) (43.81) (54.29) 
Czech Republic 154 320 125 94 442 63 153 215 231 
 (25.71) ((53.42) (20.87) (15.69) (73.79) (10.52) (25.54) (35.89) (38.56) 
Denmark 0 321 138 0 431 28 459 - - 
 (0) (69.93) (30.07) (0) (93.90) (6.10) (100)   
France 0 5040 1329 0 6315 54 6369 - - 
 (0) (79.13) (20.87) (0) (99.15) (0.85) (100)   
Greece 134 174 199 135 372 0 135 267 105 
 (26.43) (34.32) (39.25) (26.63) (73.37) (0) (26.63) (52.66) (20.71) 
Hungary 72 314 171 97 451 9 74 265 218 
 (12.93) (56.37) (30.70) (17.41) (80.97) (1.62) (13.29) (47.58) (39.14) 
Ireland1 16 641 285 14 906 22 14 550 378 
 (1.70) (68.05) (30.25) (1.49) (96.18) (2.34) (1.49) (58.39) (40.13) 
Israel 14 291 242 15 529 3 14 332 201 
 (2.56) (53.20) (44.24) (2.74) (96.71) (0.55) (2.56) (60.69) (36.75) 
Italy 765 2588 1627 771 4079 130 766 1946 2268 
 (15.36) (51.97) (32.67) (15.48) (81.91) (2.61) (15.38) (39.08) (45.54) 
Latvia 4 16 18 6 30 2 4 8 26 
 (10.53) (42.11) (47.37) (15.79) (78.95) (5.26) (10.53) (21.05) (68.42) 
Lithuania 0 11 1 0 10 2 0 3 9 
 (0) (91.67) (8.33) (0) (83.33) (16.67) (0) (25.00) (75.00) 
Rep of Macedonia 0 61 39 0 99 1 0 74 26 
 (0) (61.00) (39.00) (0) (99.00) (1.00) (0) (74.00) (26.00) 
Rep of Moldova 0 21 40 0 60 1 1 22 38 
 (0) (34.43) (65.57) (0) (98.36) (1.64) (1.64) (36.07) (62.30) 
The Netherlands 64 866 448 61 1296 21 64 710 604 
 (4.64) (62.84) (32.51) (4.43) (94.05) (1.52) (4.64) (51.52) (43.83) 
Portugal 7 167 84 7 234 17 8 142 108 
 (2.71) (64.73) (32.56) (2.71) (90.70) (6.59) (3.10) (55.04) (41.86) 
Romania 0 32 8 0 40 0 0 31 9 
 (0) (80.00) (20.00) (0) (100) (0) (0) (77.5) (22.5) 
Russian Federation 95 1377 649 95 1880 146 94 922 1105 
 (4.48) (64.92) (30.60) (4.48) (88.64) (6.88) (4.43) (43.47) (52.1) 
Serbia 1 75 78 1 134 19 1 56 97 
 (0.65) (48.70) (50.65) (0.65) (87.01) (12.34) (0.65) (36.36) (62.99) 
Slovak Republic 2 154 85 1 227 13 1 126 114 
 (0.83) (63.90) (35.27) (0.41) (94.19) (5.39) (0.41) (52.28) (47.3) 
Slovenia 2 70 12 2 81 1 2 59 23 
 (2.38) (83.33) (14.29) (2.38) (96.43) (1.19) (2.38) (70.24) (27.38) 
Spain 60 1006 415 64 1348 69 60 814 607 
 (4.05) (67.93) (28.02) (4.32) (91.02) (4.66) (4.05) (54.96) (40.99) 
Sweden 0 365 261 0 608 18 626 - - 
 (0) (58.31) (41.69) (0) (97.12) (2.88) (100)   
Switzerland 36 463 237 31 689 16 40 311 385 
 (4.89) (62.91) (32.20) (4.21) (93.61) (2.17) (5.43) (42.26) (52.31) 
Ukraine 3 59 45 3 104 0 5 37 65 
 (2.80) (55.14) (42.06) (2.80) (97.20) (0) (4.67) (34.58) (60.75) 
United Kingdom2 107 6359 2964 0 9101 329 123 7847 1460 
 (1.13) (67.43) (31.43) (0) (96.51) (3.49) (1.30) (83.21) (15.48) 
1 Ireland: chronicity is defined as: at least 4 samples recorded in the preceding 12 months and 50% or more of these 
samples being positive in the preceding 12 months. 
2 United Kingdom: chronicity for Pseudomonas aeruginosa and Staphylococcus aureus is defined as: 3 or more 
positive isolates during the last 12 months. Information on Burkholderia is collected as: Burkholderia grown at 
annual review, not necessarily chronic. 
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
56 
 
  
Table 5.1 shows, separately by country, the frequency of chronic Pseudomonas aeruginosa, chronic 
Burkholderia cepacia complex species and chronic Staphylococcus aureus. The number of missing values is 
also included. The identification rate of Burkholderia cepacia complex species in particular may also be 
influenced by differences in culture techniques employed. 
Figure 5.1 Prevalence of chronic Pseudomonas aeruginosa infection in all patients seen in 2014, by 
country.  
 
 
Note: We excluded from the graph the countries for which the information on Pseudomonas aeruginosa was 
missing for more than 10% of the patients. 
Note: Ireland: for chronic Pseudomonas aeruginosa the definition is: at least 4 samples recorded in the preceding 
12 months and 50% or more of these samples being positive in the preceding 12 months. 
 United Kingdom: for chronic Pseudomonas aeruginosa the definition is: 3 or more positive isolates during 
the last 12 months. 
 
 
The horizontal bars represent the percentage of patients with chronic Pseudomonas aeruginosa infection 
(in dark orange) and the percentage of patients where information on Pseudomonas aeruginosa infection 
was missing (in light orange). This is a frequent infection but prevalence varies considerably between 
countries. 
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Figure 5.2 Prevalence of chronic Burkholderia cepacia complex species infection in all patients seen in 
2014, by country.  
 
 
Note: We excluded from the graph the countries for which the information on Burkholderia cepacia complex 
species was missing for more than 10% of the patients. 
Note: Ireland: for chronic Burkholderia cepacia complex species the definition is: at least 4 samples recorded in 
the preceding 12 months and 50% or more of these samples being positive in the preceding 12 months. 
United Kingdom: information on Burkholderia is collected as follows: Burkholderia grown at annual review, 
not necessarily chronic. 
 
 
The horizontal bars represent the percentage of patients with chronic Burkholderia infection (in dark 
orange) and the percentage of patients where information on Burkholderia infection was missing (in light 
orange). This infection is much less frequent than Pseudomonas aeruginosa (note the different scale on 
the horizontal axis), and there is also some variation. 
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Figure 5.3 Prevalence of chronic Staphylococcus aureus infection in all patients seen in 2014, by 
country.  
 
 
Note: We excluded from the graph the countries for which the information on Staphylococcus aureus was missing 
for more than 10% of the patients. 
Note: Ireland: for chronic Staphylococcus aureus the definition is: at least 4 samples recorded in the preceding 12 
months and 50% or more of these samples being positive in the preceding 12 months. 
United Kingdom: for chronic Staphylococcus aureus the definition is: 3 or more positive isolates during the 
last 12 months.  
 
 
The horizontal bars represent the percentage of patients with chronic Staphylococcus aureus infection (in 
dark orange) and the percentage of patients where information on Staphylococcus aureus was missing (in 
light orange). This infection is as frequent as chronic Pseudomonas aeruginosa infection and a similar 
degree of variation between the countries can be observed.  
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Table 5.2 Prevalence of chronic bacterial infection in children seen in 2014, by country. 
Country Chronic Pseudomonas 
aeruginosa 
number (%) 
Chronic Burkholderia cepacia 
complex species 
number (%) 
Chronic Staphylococcus aureus 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 6 334 32 4 365 3 8 170 194 
 (1.61) (89.78) (8.60) (1.08) (98.12) (0.81) (2.15) (45.70) (52.15) 
Czech Republic 87 206 36 44 280 5 90 95 144 
 (26.44) (62.61) (10.94) (13.37) (85.11) (1.52) (27.36) (28.88) (43.77) 
Denmark 0 171 15 0 185 1 186 - - 
 (0) (91.94) (8.06) (0) (99.46) (0.54) (100)   
France 0 2818 209 0 3017 10 3027 - - 
 (0) (93.10) (6.90) (0) (99.67) (0.33) (100)   
Greece 73 128 50 73 178 0 74 145 32 
 (29.08) (51.00) (19.92) (29.08) (70.92) (0) (29.48) (57.77) (12.75) 
Hungary 10 214 83 32 273 2 11 173 123 
 (3.26) (69.71) (27.04) (10.42) (88.93) (0.65) (3.58) (56.35) (40.07) 
Ireland1 3 445 78 3 514 9 3 264 259 
 (0.57) (84.60) (14.83) (0.57) (97.72) (1.71) (0.57) (50.19) (49.24) 
Israel 4 174 59 4 232 1 4 117 116 
 (1.69) (73.42) (24.89) (1.69) (97.89) (0.42) (1.69) (49.37) (48.95) 
Italy 463 1445 307 465 1743 7 461 773 981 
 (20.90) (65.24) (13.86) (20.99) (78.69) (0.32) (20.81) (34.90) (44.29) 
Latvia 4 14 9 4 21 2 4 2 21 
 (14.81) (51.85) (33.33) (14.81) (77.78) (7.41) (14.81) (7.41) (77.78) 
Rep of Macedonia 0 49 24 0 73 0 0 56 17 
 (0) (67.12) (32.88) (0) (100) (0) (0) (76.71) (23.29) 
Rep of Moldova 0 16 31 0 46 1 0 17 30 
 (0) (34.04) (65.96) (0) (97.87) (2.13) (0) (36.17) (63.83) 
The Netherlands 4 507 88 2 591 6 4 316 279 
 (0.67) (84.64) (14.69) (0.33) (98.66) (1.00) (0.67) (52.75) (46.58) 
Portugal 2 112 41 2 142 11 3 91 61 
 (1.29) (72.26) (26.45) (1.29) (91.61) (7.10) (1.94) (58.71) (39.35) 
Romania 0 31 8 0 39 0 0 30 9 
 (0) (79.49) (20.51) (0) (100) (0) (0) (76.92) (23.08) 
Russian Federation 48 1102 345 42 1389 64 42 637 816 
 (3.21) (73.71) (23.08) (2.81) (92.91) (4.28) (2.81) (42.61) (54.58) 
Serbia 0 66 42 0 96 12 0 37 71 
 (0) (61.11) (38.89) (0) (88.89) (11.11) (0) (34.26) (65.74) 
Slovak Republic 2 89 29 1 117 2 1 60 59 
 (1.67) (74.17) (24.17) (0.83) (97.50) (1.67) (0.83) (50.00) (49.17) 
Slovenia 0 52 6 0 57 1 0 50 8 
 (0) (89.66) (10.34) (0) (98.28) (1.72) (0) (86.21) (13.79) 
Spain 12 729 119 15 819 26 12 494 354 
 (1.40) (84.77) (13.84) (1.74) (95.23) (3.02) (1.40) (57.44) (41.16) 
Sweden 0 194 40 0 231 3 234 - - 
 (0) (82.91) (17.09) (0) (98.72) (1.28) (100)   
Switzerland 12 321 49 8 372 2 15 156 211 
 (3.14) (84.03) (12.83) (2.09) (97.38) (0.52) (3.93) (40.84) (55.24) 
Ukraine 3 57 34 3 91 0 5 34 55 
 (3.19) (60.64) (36.17) (3.19) (96.81) (0) (5.32) (36.17) (58.51) 
United Kingdom2 38 3788 393 0 4155 64 50 3815 354 
 (0.90) (89.78) (9.32) (0) (98.48) (1.52) (1.19) (90.42) (8.39) 
1 Ireland: chronicity is defined as: at least 4 samples recorded in the preceding 12 months and 50% or more of these 
samples being positive in the preceding 12 months. 
2 United Kingdom: chronicity for Pseudomonas aeruginosa and Staphylococcus aureus is defined as: 3 or more 
positive isolates during the last 12 months. Information on Burkholderia is collected as follows: Burkholderia grown 
at annual review, not necessarily chronic. 
Note: for Lithuania coverage is 0% for children. 
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Table 5.2 presents, separately by country, the frequency of chronic Pseudomonas aeruginosa, chronic 
Burkholderia cepacia complex species and chronic Staphylococcus aureus in children. The number of mis-
sing values is also included. The identification rate of Burkholderia cepacia complex species in particular, 
may also be influenced by differences in culture techniques employed. 
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Table 5.3  Prevalence of chronic bacterial infection in adults seen in 2014, by country. 
Country Chronic Pseudomonas 
aeruginosa 
number (%) 
Chronic Burkholderia cepacia 
complex species 
number (%) 
Chronic Staphylococcus aureus 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 4 160 151 5 288 22 5 131 179 
 (1.27) (50.79) (47.94) (1.59) (91.43) (6.98) (1.59) (41.59) (56.83) 
Czech Republic 67 114 89 50 162 58 63 120 87 
 (24.81) (42.22) (32.96) (18.52) (60.00) (21.48) (23.33) (44.44) (32.22) 
Denmark 0 150 123 0 246 27 273 - - 
 (0) (54.95) (45.05) (0) (90.11) (9.89) (100)   
France 0 2222 1120 0 3298 44 3342 - - 
 (0) (66.49) (33.51) (0) (98.68) (1.32) (100)   
Greece 61 46 149 62 194 0 61 122 73 
 (23.83) (17.97) (58.20) (24.22) (75.78) (0) (23.83) (47.66) (28.52) 
Hungary 62 99 88 65 177 7 63 91 95 
 (24.90) (39.76) (35.34) (26.10) (71.08) (2.81) (25.30) (36.55) (38.15) 
Ireland1 13 196 207 11 392 13 11 286 119 
 (3.13) (47.12) (49.76) (2.64) (94.23) (3.13) (2.64) (68.75) (28.61) 
Israel 10 117 183 11 297 2 10 215 85 
 (3.23) (37.74) (59.03) (3.55) (95.81) (0.65) (3.23) (69.35) (27.42) 
Italy 302 1143 1320 306 2336 123 305 1173 1287 
 (10.92) (41.34) (47.74) (11.07) (84.48) (4.45) (11.03) (42.42) (46.55) 
Latvia 0 2 9 2 9 0 0 6 5 
 (0) (18.18) (81.82) (18.18) (81.82) (0) (0) (54.55) (45.45) 
Lithuania 0 11 1 0 10 2 0 3 9 
 (0) (91.67) (8.33) (0) (83.33) (16.67) (0) (25.00) (75.00) 
Rep of Macedonia 0 12 15 0 26 1 0 18 9 
 (0) (44.44) (55.56) (0) (96.3)0 (3.70) (0) (66.67) (33.33) 
Rep of Moldova 0 5 9 0 14 0 1 5 8 
 (0) (35.71) (64.29) (0) (100) (0) (7.14) (35.71) (57.14) 
The Netherlands 60 359 360 59 705 15 60 394 325 
 (7.70) (46.08) (46.21) (7.57) (90.50) (1.93) (7.70) (50.58) (41.72) 
Portugal 5 55 43 5 92 6 5 51 47 
 (4.85) (53.40) (41.75) (4.85) (89.32 (5.83) (4.85) (49.51) (45.63) 
Russian Federation 47 275 304 53 491 82 52 285 289 
 (7.51) (43.93) (48.56) (8.47) (78.43) (13.10) (8.31) (45.53) (46.17) 
Serbia 1 9 36 1 38 7 1 19 26 
 (2.17) (19.57) (78.26) (2.17) (82.61) (15.22) (2.17) (41.30) (56.52) 
Slovak Republic 0 65 56 0 110 11 0 66 55 
 (0) (53.72) (46.28) (0) (90.91) (9.09) (0) (54.55) (45.45) 
Slovenia 2 18 6 2 24 0 2 9 15 
 (7.69) (69.23) (23.08) (7.69) (92.31) (0) (7.69) (34.62) (57.69) 
Spain 48 277 296 49 529 43 48 320 253 
 (7.73) (44.61) (47.67) (7.89) (85.19) (6.92) (7.73) (51.53) (40.74) 
Sweden 0 171 221 0 377 15 392 - - 
 (0) (43.62) (56.38) (0) (96.17) (3.83) (100)   
Switzerland 24 142 188 23 317 14 25 155 174 
 (6.78) (40.11) (53.11) (6.50) (89.55) (3.95) (7.06) (43.79) (49.15) 
Ukraine 0 2 11 0 13 0 0 3 10 
 (0) (15.38) (84.62) (0) (100) (0) (0) (23.08) (76.92) 
United Kingdom2 69 2571 2571 0 4946 265 73 4032 1106 
 (1.32) (49.34) (49.34) (0) (94.91) (5.09) (1.40) (77.37) (21.22) 
1 Ireland: chronicity is defined as: at least 4 samples recorded in the preceding 12 months and 50% or more of these 
samples being positive in the preceding 12 months. 
2 United Kingdom: chronicity for Pseudomonas aeruginosa and Staphylococcus aureus is defined as: 3 or more 
positive isolates during the last 12 months. Information on Burkholderia is collected as follows: Burkholderia grown 
at annual review, not necessarily chronic. 
Note: Romania has only one adult patient and is excluded from the table. 
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Table 5.3 shows, separately by country, the frequency of chronic Pseudomonas aeruginosa, chronic 
Burkholderia cepacia complex species and chronic Staphylococcus aureus in adults. The number of missing 
values is also included. The identification rate of Burkholderia cepacia complex species in particular may 
also be influenced by differences in culture techniques employed. 
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Table 5.4 Prevalence of non-tuberculous mycobacteria and Stenotrophomonas maltophilia infection 
in all patients seen in 2014, by country. 
Country Non-tuberculous mycobacteria 
(NTM) infection this year 
number (%) 
Stenotrophomonas maltophilia  
infection this year 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 47 609 31 10 614 63 
 (6.84) (88.65) (4.51) (1.46) (89.37) (9.17) 
Czech Republic 338 242 19 91 437 71 
 (56.43) (40.40) (3.17) (15.19) (72.95) (11.85) 
Denmark 459 - - 459 - - 
 (100)   (100)   
France 0 6234 135 0 5724 645 
 (0) (97.88) (2.12) (0) (89.87) (10.13) 
Greece 360 144 3 136 342 29 
 (71.01) (28.40) (0.59) (26.82) (67.46) (5.72) 
Hungary 130 422 5 83 461 13 
 (23.34) (75.76) (0.90) (14.90) (82.76) (2.33) 
Ireland 14 917 11 14 842 86 
 (1.49) (97.35) (1.17) (1.49) (89.38) (9.13) 
Israel 14 490 43 13 502 32 
 (2.56) (89.58) (7.86) (2.38) (91.77) (5.85) 
Italy 771 4179 30 771 3976 233 
 (15.48) (83.92) (0.60) (15.48) (79.84) (4.68) 
Latvia 4 34 0 4 32 2 
 (10.53) (89.47) (0) (10.53) (84.21) (5.26) 
Lithuania 0 12 0 0 11 1 
 (0) (100) (0) (0) (91.67) (8.33) 
Rep of Macedonia 0 100 0 0 95 5 
 (0) (100) (0) (0) (95.00) (5.00) 
Rep of Moldova 61 - - 0 58 3 
 (100)   (0) (95.08) (4.92) 
The Netherlands 123 1234 21 64 1142 172 
 (8.93) (89.55) (1.52) (4.64) (82.87) (12.48) 
Portugal 21 231 6 7 224 27 
 (8.14) (89.53) (2.33) (2.71) (86.82) (10.47) 
Romania 0 40 0 0 40 0 
 (0) (100) (0) (0) (100) (0) 
Russian Federation 755 1356 10 100 1955 66 
 (35.6) (63.93) (0.47) (4.71) (92.17) (3.11) 
Serbia 1 153 0 1 143 10 
 (0.65) (99.35) (0) (0.65) (92.86) (6.49) 
Slovak Republic 2 238 1 3 224 14 
 (0.83) (98.76) (0.41) (1.24) (92.95) (5.81) 
Slovenia 8 74 2 13 66 5 
 (9.52) (88.10) (2.38) (15.48) (78.57) (5.95) 
Spain 292 1144 45 64 1307 110 
 (19.72) (77.25) (3.04) (4.32) (88.25) (7.43) 
Sweden 0 596 30 0 573 53 
 (0) (95.21) (4.79) (0) (91.53) (8.47) 
Switzerland 46 664 26 32 624 80 
 (6.25) (90.22) (3.53) (4.35) (84.78) (10.87) 
Ukraine 107 - - 2 102 3 
 (100)   (1.87) (95.33) (2.80) 
United Kingdom 0 8847 583 0 8837 593 
 (0) (93.82) (6.18) (0) (93.71) (6.29) 
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Table 5.4 shows the frequency of two other infections, non-tuberculous mycobacteria (NTM) and 
Stenotrophomonas maltophilia. Both these infections seem to be relatively rare, in line with the 
frequencies of Burkholderia infection. The identification rate of these bacteria may also be influenced by 
differences in culture techniques employed. 
 
Figure 5.4  Prevalence of non-tuberculous mycobacteria in all patients seen in 2014, by country.  
 
 
Note: We excluded from the graph the countries for which the information on non-tuberculous mycobacteria was 
missing for more than 10% of the patients. 
 
 
The horizontal bars represent the percentage of patients with non-tuberculous mycobacteria infection (in 
dark orange) and the percentage of patients where information on non-tuberculous mycobacteria 
infection was missing (in light orange). Generally, infections from these bacteria are not very frequent in 
any country.  
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Figure 5.5 Prevalence of Stenotrophomonas maltophilia infection in all patients seen in 2014, by 
country.  
 
 
Note: We excluded from the graph the countries for which the information on Stenotrophomonas maltophilia was 
missing for more than 10% of the patients. 
 
 
The horizontal bars represent the percentage of patients with Stenotrophomonas maltophilia infection (in 
dark orange) and the percentage of patients where information on Stenotrophomonas maltophilia was 
missing (light orange). The frequency varies considerably between countries.  
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Table 5.5 Prevalence of non-tuberculous mycobacteria and Stenotrophomonas maltophilia infection 
in children seen in 2014, by country. 
Country Non-tuberculous mycobacteria 
(NTM) infection this year 
number (%) 
Stenotrophomonas maltophilia  
infection this year 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 28 334 10 3 340 29 
 (7.53) (89.78) (2.69) (0.81) (91.4) (7.80) 
Czech Republic 269 59 1 41 244 44 
 (81.76) (17.93) (0.30) (12.46) (74.16) (13.37) 
Denmark 186 - - 186 - - 
 (100)   (100)   
France 0 2989 38 0 2688 339 
 (0) (98.74) (1.26) (0) (88.80) (11.20) 
Greece 179 72 0 73 170 8 
 (71.31) (28.69) (0) (29.08) (67.73) (3.19) 
Hungary 68 239 0 21 280 6 
 (22.15) (77.85) (0) (6.84) (91.21) (1.95) 
Ireland 3 517 6 3 465 58 
 (0.57) (98.29) (1.14) (0.57) (88.4) (11.03) 
Israel 4 219 14 4 216 17 
 (1.69) (92.41) (5.91) (1.69) (91.14) (7.17) 
Italy 465 1743 7 465 1645 105 
 (20.99) (78.69) (0.32) (20.99) (74.27) (4.74) 
Latvia 4 23 0 4 22 1 
 (14.81) (85.19) (0) (14.81) (81.48) (3.70) 
Rep of Macedonia 0 73 0 0 68 5 
 (0) (100) (0) (0) (93.15) (6.85) 
Rep of Moldova 47 - - 0 45 2 
 (100)   (0) (95.74) (4.26) 
The Netherlands 26 563 10 3 516 80 
 (4.34) (93.99) (1.67) (0.50) (86.14) (13.36) 
Portugal 15 139 1 2 134 19 
 (9.68) (89.68) (0.65) (1.29) (86.45) (12.26) 
Romania 0 39 0 0 39 0 
 (0) (100) (0) (0) (100) (0) 
Russian Federation 525 968 2 42 1409 44 
 (35.12) (64.75) (0.13) (2.81) (94.25) (2.94) 
Serbia 0 108 0 0 98 10 
 (0) (100) (0) (0) (90.74) (9.26) 
Slovak Republic 1 119 0 1 116 3 
 (0.83) (99.17) (0) (0.83) (96.67) (2.50) 
Slovenia 0 57 1 0 56 2 
 (0) (98.28) (1.72) (0) (96.55) (3.45) 
Spain 161 677 22 15 778 67 
 (18.72) (78.72) (2.56) (1.74) (90.47) (7.79) 
Sweden 0 226 8 0 217 17 
 (0) (96.58) (3.42) (0) (92.74) (7.26) 
Switzerland 13 366 3 8 340 34 
 (3.40) (95.81) (0.79) (2.09) (89.01) (8.90) 
Ukraine 94 - - 2 89 3 
 (100)   (2.13) (94.68) (3.19) 
United Kingdom 0 4073 146 0 3962 257 
 (0) (96.54) (3.46) (0) (93.91) (6.09) 
 
Note: For Lithuania coverage is 0% for children. 
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Table 5.6 Prevalence of non-tuberculous mycobacteria and Stenotrophomonas maltophilia infection 
in adults seen in 2014, by country. 
Country Non-tuberculous mycobacteria 
(NTM) infection this year 
number (%) 
Stenotrophomonas maltophilia  
infection this year 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 19 275 21 7 274 34 
 (6.03) (87.30) (6.67) (2.22) (86.98) (10.79) 
Czech Republic 69 183 18 50 193 27 
 (25.56) (67.78) (6.67) (18.52) (71.48) (10.00) 
Denmark 273 - - 273 - - 
 (100)   (100)   
France 0 3245 97 0 3036 306 
 (0) (97.10) (2.90) (0) (90.84) (9.16) 
Greece 181 72 3 63 172 21 
 (70.70) (28.13) (1.17) (24.61) (67.19) (8.20) 
Hungary 62 182 5 62 180 7 
 (24.90) (73.09) (2.01) (24.90) (72.29) (2.81) 
Ireland 11 400 5 11 377 28 
 (2.64) (96.15) (1.20) (2.64) (90.63) (6.73) 
Israel 10 271 29 9 286 15 
 (3.23) (87.42) (9.35) (2.90) (92.26) (4.84) 
Italy 306 2436 23 306 2331 128 
 (11.07) (88.10) (0.83) (11.07) (84.30) (4.63) 
Latvia 0 11 0 0 10 1 
 (0) (100) (0) (0) (90.91) (9.09) 
Lithuania 0 12 0 0 11 1 
 (0) (100) (0) (0) (91.67) (8.33) 
Rep of Macedonia 0 27 0 0 27 0 
 (0) (100) (0) (0) (100) (0) 
Rep of Moldova 14 - - 0 13 1 
 (100)   (0) (92.86) (7.14) 
The Netherlands 97 671 11 61 626 92 
 (12.45) (86.14) (1.41) (7.83) (80.36) (11.81) 
Portugal 6 92 5 5 90 8 
 (5.83) (89.32) (4.85) (4.85) (87.38) (7.77) 
Russian Federation 230 388 8 58 546 22 
 (36.74) (61.98) (1.28) (9.27) (87.22) (3.51) 
Serbia 1 45 0 1 45 0 
 (2.17) (97.83) (0) (2.17) (97.83) (0) 
Slovak Republic 1 119 1 2 108 11 
 (0.83) (98.35) (0.83) (1.65) (89.26) (9.09) 
Slovenia 8 17 1 13 10 3 
 (30.77) (65.38) (3.85) (50) (38.46) (11.54) 
Spain 131 467 23 49 529 43 
 (21.10) (75.20) (3.70) (7.89) (85.19) (6.92) 
Sweden 0 370 22 0 356 36 
 (0) (94.39) (5.61) (0) (90.82) (9.18) 
Switzerland 33 298 23 24 284 46 
 (9.32) (84.18) (6.50) (6.78) (80.23) (12.99) 
Ukraine 13 - - 0 13 0 
 (100)   (0) (100) (0) 
United Kingdom 0 4774 437 0 4875 336 
 (0) (91.61) (8.39) (0) (93.55) (6.45) 
 
 Note: Romania has only one adult patient and is excluded from the table.  
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6. Nutrition 
Pancreatic insufficiency is usually defined as absence of pancreatic enzymes in two stool samples (or 
elevated levels of fat in stools). However, since information on both was rarely collected by the national 
registries, we used information on the use of pancreatic enzymes as an indicator of pancreatic 
insufficiency. 
We collected weight and height measured at the time when the FEV1 value was recorded, and, for patients 
that did not perform spirometry, the last measurements in the year were considered. From these raw 
values we calculated body mass index (BMI). A patient with a low weight is not necessarily underweight if 
the height is also low, and BMI may better illustrate the nutritional status: BMI describes the weight/height 
relationship and is considered a good measure of nutritional status. The ECFS Standards of Care 
recommend BMI of greater than 20 kg/(m2). 2 
Weight, height and BMI were then expressed in terms of so-called z-scores by using a reference population 
of healthy individuals (in this case the US population with reference values issued by the Centre for Disease 
Control, USA, see Appendix 1, page 120, for details). 
A z-score of 0 means that the height/weight/BMI is equal to the mean height/weight/BMI of people of the 
same age and sex of the reference population. A z-score of -2 means that the height/weight/BMI value is 
2 standard deviations below the mean height/weight/BMI of people of the same age and sex of the 
reference population; a z-score of +2 means that the value is 2 standard deviations above that mean. In 
the reference population, 95% of all individuals have a z-score for weight between -2 and +2 (the same for 
height) and it is expected that the same happens for approximately 95% of individuals of a population 
without conditions that affect weight (or height). The average z-score for a largely healthy population 
should be very close to zero. 
 
 
 
 
 
 
 
 
 
 
 
2 A.R. Smyth et al, JCF 2014;13, S23–S42 
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Figure 6.1 Use of pancreatic enzymes in 2014 for all patients, by country and overall. 
 
 
Note: For Greece and Italy the information on use of pancreatic enzymes is missing for more than 10% of the 
patients. 
 
 
This graph shows the use of pancreatic enzymes by country. This can be seen as an informed estimate of 
pancreatic insufficiency.  
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Table 6.1 Number of patients for whom height and weight measurements were available. All patients 
seen in 2014. 
Country Number of 
patients 
Height Weight 
N N miss N N miss 
Austria 687 657 30 658 29 
Czech Republic 599 534 65 530 69 
Denmark 459 451 8 451 8 
France 6369 6171 198 6146 223 
Greece 507 365 142 364 143 
Hungary 557 500 57 505 52 
Ireland 942 887 55 862 80 
Israel 547 507 40 508 39 
Italy 4980 4056 924 4054 926 
Latvia 38 21 17 21 17 
Lithuania 12 12 0 12 0 
Rep of Macedonia 100 99 1 99 1 
Rep of Moldova 61 61 0 61 0 
The Netherlands 1378 1368 10 1347 31 
Portugal 258 241 17 241 17 
Romania 40 40 0 40 0 
Russian Federation 2121 1967 154 1990 131 
Serbia 154 148 6 149 5 
Slovak Republic 241 208 33 208 33 
Slovenia 84 82 2 82 2 
Spain 1481 1360 121 1362 119 
Sweden 626 623 3 622 4 
Switzerland 736 714 22 714 22 
Ukraine 107 103 4 103 4 
United Kingdom 9430 9275 155 9296 134 
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Table 6.2 Z-scores for height: descriptive statistics by country. Patients aged 17 years or younger. 
Country N Mean Min 25th pctl 
 
(25% of the 
patients are 
below this z-
score for 
height) 
Median 
 
(50% of the 
patients are 
below this z-
score for 
height) 
75th pctl 
 
(75% of the 
patients are 
below this z-
score for 
height) 
Max 
Austria 361 -0.1 -3.7 -0.7 -0.1 0.7 4.9 
Czech Republic 325 0.1 -5.5 -0.7 0.0 0.9 4.5 
Denmark 191 -0.1 -2.9 -0.6 -0.2 0.6 2.6 
France 3002 -0.5 -5.1 -1.2 -0.5 0.2 4.2 
Greece 162 -0.2 -4.0 -0.9 -0.2 0.6 3.0 
Hungary 295 0.0 -4.4 -0.8 0.0 0.8 6.3 
Ireland 507 -0.3 -4.2 -0.9 -0.3 0.3 2.6 
Israel 225 -0.5 -3.0 -1.2 -0.4 0.2 2.7 
Italy 1610 -0.3 -4.0 -1.0 -0.2 0.4 3.7 
Latvia 15 -0.1 -1.7 -0.6 -0.2 0.4 1.3 
Rep of Macedonia 77 -0.7 -4.4 -1.5 -1.0 0.3 1.5 
Rep of Moldova 48 -1.4 -9.5 -2.3 -1.4 -0.3 2.3 
The Netherlands 616 0.2 -5.5 -0.4 0.3 0.9 3.6 
Portugal 150 -0.6 -4.3 -1.2 -0.7 0.2 3.7 
Romania 39 -0.1 -2.5 -1.0 -0.2 0.9 2.1 
Russian Federation 1439 -0.6 -7.0 -1.4 -0.5 0.3 5.7 
Serbia 109 -0.4 -6.8 -1.1 -0.3 0.5 2.9 
Slovak Republic 91 0.3 -2.3 -0.5 0.2 1.0 3.0 
Slovenia 60 0.0 -2.6 -0.8 -0.1 0.7 3.6 
Spain 798 -0.3 -4.8 -1.0 -0.3 0.4 2.8 
Sweden 242 0.0 -2.3 -0.7 0.0 0.5 3.5 
Switzerland 388 -0.4 -4.2 -1.0 -0.3 0.2 2.5 
Ukraine 92 -0.5 -3.6 -1.4 -0.6 0.1 3.4 
United Kingdom 4200 -0.4 -8.1 -1.2 -0.4 0.3 5.9 
 
Note: For Lithuania coverage is 0% for children. 
 
This table reports the median z-score for height (the value that separates the highest and lowest half of 
the patients), the mean z-score for height (the average) and other descriptive statistics for children (17 
years or younger). 
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Table 6.3  Z-scores for height: descriptive statistics by country. Patients aged 18 years or older. 
Country N Mean Min 25th pctl 
 
(25% of the 
patients are 
below this  
z-score for 
height) 
Median 
 
(50% of the 
patients are 
below this  
z-score for 
height) 
75th pctl 
 
(75% of the 
patients are 
below this  
z-score for 
height) 
Max 
Austria 296 -0.3 -4.2 -0.8 -0.3 0.3 2.6 
Czech Republic 209 -0.1 -2.9 -0.7 -0.1 0.4 3.1 
Denmark 260 0.1 -2.5 -0.6 0.1 0.8 3.2 
France 3169 -0.5 -5.7 -1.2 -0.5 0.1 3.0 
Greece 203 -0.5 -2.8 -1.1 -0.5 0.2 2.0 
Hungary 205 -0.1 -3.4 -1.0 -0.1 0.6 3.6 
Ireland 380 -0.4 -4.9 -1.0 -0.4 0.3 2.0 
Israel 282 -0.6 -4.3 -1.3 -0.6 0.1 1.6 
Italy 2446 -0.6 -4.4 -1.2 -0.5 0.1 3.7 
Latvia <10 0.5 -0.7 -0.4 0.6 1.2 1.4 
Lithuania 12 0.5 -2.1 -0.2 0.3 1.4 2.4 
Rep of Macedonia 22 -0.6 -2.7 -1.2 -0.7 -0.3 2.3 
Rep of Moldova 13 -0.2 -2.3 -1.0 -0.4 1.0 2.0 
The Netherlands 752 0.3 -3.4 -0.4 0.4 1.0 3.9 
Portugal 91 -0.8 -3.0 -1.5 -1.0 -0.1 1.3 
Russian Federation 528 -0.3 -4.8 -1.0 -0.3 0.4 3.4 
Serbia 39 0.0 -2.6 -0.6 -0.1 0.6 2.4 
Slovak Republic 117 0.0 -4.1 -0.5 0.1 0.9 2.4 
Slovenia 22 0.0 -1.5 -0.8 0.2 0.6 2.4 
Spain 562 -0.7 -3.8 -1.3 -0.7 -0.1 2.1 
Sweden 381 0.1 -2.9 -0.5 0.2 0.7 3.3 
Switzerland 326 -0.2 -3.7 -0.8 -0.2 0.4 2.4 
Ukraine 11 -0.4 -1.4 -0.8 -0.5 0.1 0.6 
United Kingdom 5075 -0.4 -4.9 -1.0 -0.4 0.3 3.5 
 
Note: Romania has only one adult patient and is excluded from the table. 
 
This table reports the median z-score for height (the value that separates the highest and lowest half of 
the patients), the mean z-score for height (the average), and other descriptive statistics for adults (18 years 
or older).  
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Figure 6.2  Median z-scores for height by age group and by country. All patients seen in 2014. 
 
 
Note: We excluded from the analyses those age groups where the number of patients was <10. 
 
 
This graph shows the median z-scores for height by age group. Each country is represented by a dot (in 
blue) and the overall estimate is in red. The median z-scores for height tend to slowly decrease up to the 
teenage years and then rise again before levelling out. Since the z-scores are computed using healthy 
people as a reference, this pattern can be explained by the fact that CF patients reach the puberty growth 
spurt later than their peers, but then catch up. The graph also shows that there is large variability between 
countries. 
 
Table 6.4 Z-scores for height: descriptive statistics by age group. All patients seen in 2014. 
Age at height 
measurement 
N Mean 
 
Min 25th pctl 
 
Median 
 
75th pctl 
 
Max 
0-4 3659 -0.3 -9.5 -1.1 -0.3 0.5 6.3 
5-9 4574 -0.2 -6.2 -0.9 -0.2 0.4 3.8 
10-14 4267 -0.4 -7.4 -1.2 -0.4 0.3 5.9 
15-19 4174 -0.5 -5.7 -1.2 -0.5 0.2 2.9 
20-24 3856 -0.4 -4.6 -1.1 -0.5 0.3 3.9 
25-29 3157 -0.4 -5.1 -1.1 -0.4 0.3 3.4 
30-34 2357 -0.3 -5.7 -1.0 -0.4 0.4 3.6 
35-39 1646 -0.3 -4.1 -1.0 -0.3 0.4 3.3 
40-44 1157 -0.3 -3.7 -1.0 -0.3 0.4 2.7 
45+ 1603 -0.3 -4.9 -1.0 -0.3 0.4 3.3 
 
This table reports the median z-score for height and other descriptive statistics by age group for all the 
patients seen in 2014. The median values reported in this table are shown as red dots in fig 6.2.  
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Figure 6.3 Quartiles of z-scores for height by age group and by country. All patients seen in 2014. 
The figures below show the z-scores for height by country. The dot is the median and the whiskers show 
the 25th and 75th percentiles. In blue are the quartiles for the country, in red are the pooled quartiles 
computed on all other countries (i.e. excluding that country). We did not compute quartiles where the 
number of patients in the age group is <10, therefore there are no blue dots for those age groups (the 
number of patients in each age group is shown underneath the horizontal axis). We therefore excluded 
Latvia and Lithuania from the graphs because none of the age groups in these countries had more than 10 
patients. 
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[figure 6.3 continued] 
 
Quartiles of z-scores for height: Italy 
 
Quartiles of z-scores for height: Rep of Macedonia 
  
 
Quartiles of z-scores for height: Rep of Moldova 
 
Quartiles of z-scores for height: The Netherlands 
  
 
Quartiles of z-scores for height: Portugal 
 
Quartiles of z-scores for height: Romania 
  
 
    Quartiles of z-scores for height: Russian Federation 
 
Quartiles of z-scores for height: Serbia 
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[figure 6.3 continued] 
 
Quartiles of z-scores for height: Slovak Republic 
 
Quartiles of z-scores for height: Slovenia 
  
 
Quartiles of z-scores for height: Spain 
 
Quartiles of z-scores for height: Sweden 
  
 
Quartiles of z-scores for height: Switzerland 
 
Quartiles of z-scores for height: Ukraine 
  
 
Quartiles of z-scores for height: United Kingdom 
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Table 6.5 Z-scores for weight: descriptive statistics by country. Patients aged 17 years or younger. 
Country N Mean Min 25th pctl 
 
(25% of the 
patients are 
below this  
z-score for 
weight) 
Median 
 
(50% of the 
patients are 
below this  
z-score for 
weight) 
75th pctl 
 
(75% of the 
patients are 
below this 
 z-score for 
weight) 
Max 
Austria 361 -0.4 -4.6 -1.0 -0.3 0.4 2.7 
Czech Republic 325 -0.1 -5.0 -0.8 -0.1 0.6 5.9 
Denmark 191 -0.3 -3.7 -1.0 -0.3 0.3 1.8 
France 3005 -0.6 -5.4 -1.3 -0.6 0.1 5.7 
Greece 162 0.0 -3.6 -0.8 0.1 0.8 3.1 
Hungary 300 -0.7 -9.7 -1.6 -0.6 0.2 4.2 
Ireland 519 -0.1 -4.3 -0.8 -0.1 0.6 2.6 
Israel 226 -0.4 -3.3 -1.2 -0.4 0.3 2.3 
Italy 1610 -0.3 -8.5 -1.0 -0.2 0.5 3.0 
Latvia 15 -0.8 -2.9 -1.3 -0.7 -0.1 0.4 
Rep of Macedonia 77 -0.4 -4.2 -1.3 -0.5 0.4 2.4 
Rep of Moldova 48 -1.3 -8.6 -2.1 -1.1 0.1 2.6 
The Netherlands 616 0.0 -5.3 -0.6 0.1 0.6 3.1 
Portugal 150 -0.7 -8.8 -1.4 -0.6 0.1 2.5 
Romania 39 -0.7 -4.1 -1.5 -0.7 0.3 1.9 
Russian Federation 1460 -0.9 -9.4 -1.7 -0.8 0.0 3.4 
Serbia 110 -0.6 -9.3 -1.3 -0.4 0.4 2.3 
Slovak Republic 91 -0.3 -2.7 -1.0 -0.3 0.4 2.3 
Slovenia 60 -0.6 -7.1 -1.3 -0.5 0.2 2.0 
Spain 799 -0.4 -4.8 -1.0 -0.4 0.4 4.3 
Sweden 242 -0.2 -3.2 -0.7 -0.1 0.5 2.6 
Switzerland 388 -0.5 -4.0 -1.1 -0.4 0.3 2.6 
Ukraine 92 -1.0 -7.1 -1.8 -1.0 -0.3 1.8 
United Kingdom 4290 -0.3 -8.5 -1.0 -0.2 0.5 8.5 
 
Note: For Lithuania coverage is 0% for children. 
 
This table reports the median z-score for weight (the value that separates the highest and lowest half of 
the patients), the mean z-score for weight (the average), and other descriptive statistics for children (17 
years or younger). 
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Table 6.6  Z-scores for weight: descriptive statistics by country. Patients aged 18 years or older. 
Country N Mean Min 25th pctl 
 
(25% of the 
patients are 
below this  
z-score for 
weight) 
Median 
 
(50% of the 
patients are 
below this  
z-score for 
weight) 
75th pctl 
 
(75% of the 
patients are 
below this  
z-score for 
weight) 
Max 
Austria 297 -0.6 -6.4 -1.3 -0.5 0.2 2.4 
Czech Republic 205 -0.6 -5.8 -1.3 -0.5 0.2 2.0 
Denmark 260 -0.3 -3.8 -1.0 -0.2 0.5 2.0 
France 3141 -0.8 -8.2 -1.6 -0.7 -0.1 2.8 
Greece 202 -0.6 -5.4 -1.3 -0.4 0.2 2.0 
Hungary 205 -0.9 -7.3 -1.7 -0.9 0.2 1.8 
Ireland 343 -0.3 -5.8 -0.9 -0.3 0.4 2.2 
Israel 282 -0.5 -4.6 -1.2 -0.4 0.4 2.2 
Italy 2444 -0.6 -6.8 -1.2 -0.5 0.2 3.2 
Latvia <10 -0.5 -1.2 -1.2 -0.6 0.0 0.4 
Lithuania 12 -0.7 -3.0 -1.2 -0.3 0.0 0.6 
Rep of Macedonia 22 -0.9 -2.6 -1.2 -0.8 -0.4 0.9 
Rep of Moldova 13 -1.4 -4.1 -2.8 -1.1 -0.3 0.4 
The Netherlands 731 -0.1 -4.4 -0.6 0.0 0.6 2.5 
Portugal 91 -0.6 -4.4 -1.2 -0.5 0.2 2.2 
Russian Federation 530 -1.3 -6.5 -2.1 -1.2 -0.4 2.4 
Serbia 39 -1.1 -5.8 -1.3 -1.0 -0.4 1.2 
Slovak Republic 117 -0.5 -4.4 -1.3 -0.3 0.4 2.3 
Slovenia 22 -0.7 -2.1 -1.3 -0.7 -0.1 0.7 
Spain 563 -0.6 -5.4 -1.3 -0.6 0.1 3.6 
Sweden 380 -0.1 -4.6 -0.7 0.0 0.6 2.9 
Switzerland 326 -0.6 -7.6 -1.2 -0.5 0.1 2.3 
Ukraine 11 -1.7 -4.9 -1.8 -1.4 -0.9 -0.6 
United Kingdom 5006 -0.3 -8.9 -0.9 -0.2 0.5 3.8 
 
Note: Romania has only one adult patient and is excluded from the table. 
 
This table reports the median z-score for weight (the value that separates the highest and lowest half of 
the patients), the mean z-score for weight (the average), and other descriptive statistics for adults (18 
years or older). 
  
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
79 
 
  
Figure 6.4 Median z-scores for weight by age group and by country. All patients seen in 2014. 
 
 
Note: We excluded from the analyses those age groups where the number of patients was <10. 
 
 
This graph shows the median z-scores for weight by age group. Each country is represented by a dot (in 
blue) and the overall estimate is in red. Overall, the median z-scores for weight decrease from the third 
youngest age group to the 20-24 years age group before they increase in the older age groups. Again, the 
patients in the oldest age groups are patients that survived, and may therefore represent the patients with 
less disease severity. There is considerable variability between countries. 
 
Table 6.7 Z-scores for weight: descriptive statistics by age group. All patients seen in 2014. 
Age at weight 
measurement 
N Mean Min 25th pctl 
 
Median 75th pctl Max 
0-4 3740 -0.4 -9.4 -1.2 -0.3 0.4 8.5 
5-9 4586 -0.2 -5.2 -0.9 -0.2 0.5 3.1 
10-14 4280 -0.5 -8.5 -1.2 -0.4 0.3 3.4 
15-19 4186 -0.7 -9.7 -1.4 -0.6 0.1 2.5 
20-24 3819 -0.8 -7.6 -1.5 -0.7 0.0 2.8 
25-29 3127 -0.7 -7.2 -1.3 -0.5 0.2 3.6 
30-34 2334 -0.4 -8.9 -1.1 -0.4 0.3 3.1 
35-39 1628 -0.3 -6.2 -1.0 -0.2 0.4 3.8 
40-44 1136 -0.1 -5.2 -0.8 -0.1 0.6 2.7 
45+ 1589 0.0 -5.5 -0.6 0.1 0.8 2.9 
 
This table reports the median z-score for weight and other descriptive statistics by age group for all the 
patients seen in 2014. The median values reported in this table are shown as red dots in fig 6.4.  
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Figure 6.5 Quartiles of z-scores for weight by age group and by country. All patients seen in 2014. 
The figures below show the z-scores for weight by country. The dot is the median, and the whiskers show 
the 25th and 75th percentiles. In blue are the quartiles for the country, in red are the pooled quartiles 
computed on all other countries (i.e. excluding that country). We did not compute quartiles where the 
number of patients in the age group is <10. Therefore, there are no blue dots for those age groups (the 
number of patients in each age group is shown underneath the horizontal axis). We excluded Latvia and 
Lithuania from the graphs because none of the age groups in these countries had more than 10 patients. 
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 [figure 6.5 continued] 
 
Quartiles of z-scores for weight: Italy 
 
Quartiles of z-scores for weight: Rep of Macedonia 
  
 
Quartiles of z-scores for weight: Rep of Moldova 
 
Quartiles of z-scores for weight: The Netherlands 
  
 
Quartiles of z-scores for weight: Portugal 
 
Quartiles of z-scores for weight: Romania 
  
 
Quartiles of z-scores for weight: Russian Federation 
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[figure 6.5 continued] 
 
Quartiles of z-scores for weight: Slovak Republic 
 
Quartiles of z-scores for weight: Slovenia 
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Table 6.8 Z-scores for BMI: descriptive statistics by country. All patients seen in 2014 aged 2-17 years. 
Country N N Miss Mean Min 25th pctl 
 
(25% of the 
patients are 
below this  
z-score for 
BMI) 
Median 
 
(50% of the 
patients are 
below this  
z-score for 
BMI) 
75th pctl 
 
(75% of the 
patients are 
below this  
z-score for 
BMI) 
Max 
Austria 329 0 -0.4 -6.7 -1.1 -0.3 0.4 1.9 
Czech Republic 288 1 -0.3 -3.9 -0.9 -0.1 0.5 2.0 
Denmark 180 0 -0.4 -4.0 -1.1 -0.4 0.4 2.2 
France 2782 9 -0.4 -5.6 -1.1 -0.4 0.2 2.5 
Greece 158 0 0.3 -3.3 -0.3 0.3 1.0 2.6 
Hungary 272 3 -1.0 -7.0 -1.7 -0.8 -0.1 2.4 
Ireland 459 22 0.1 -3.6 -0.5 0.1 0.7 2.9 
Israel 220 0 -0.2 -3.3 -1.0 -0.2 0.4 2.1 
Italy 1559 53 -0.1 -5.6 -0.8 -0.1 0.6 3.1 
Latvia 15 0 -1.0 -2.4 -2.1 -0.9 -0.4 0.2 
Rep of Macedonia 69 0 0.1 -2.9 -0.6 -0.1 0.7 2.5 
Rep of Moldova 42 0 -0.4 -6.6 -1.1 -0.3 0.6 2.9 
The Netherlands 560 2 -0.1 -3.4 -0.7 -0.1 0.5 2.5 
Portugal 137 0 -0.5 -6.5 -1.0 -0.4 0.2 2.4 
Romania 33 0 -0.7 -3.7 -1.5 -0.6 0.2 1.6 
Russian Federation 1223 15 -0.7 -9.4 -1.5 -0.6 0.2 3.6 
Serbia 101 0 -0.4 -4.7 -1.1 -0.2 0.4 2.0 
Slovak Republic 88 0 -0.5 -3.9 -1.2 -0.5 0.2 2.2 
Slovenia 56 0 -0.7 -4.6 -1.5 -0.6 0.2 1.6 
Spain 701 4 -0.2 -4.0 -0.8 -0.2 0.5 2.3 
Sweden 227 0 -0.2 -3.4 -0.6 -0.1 0.4 2.1 
Switzerland 341 1 -0.3 -3.9 -0.9 -0.2 0.4 2.3 
Ukraine 83 0 -1.1 -6.2 -1.6 -0.9 -0.4 1.2 
United Kingdom 3924 100 0.0 -9.3 -0.6 0.1 0.7 5.5 
 
  Note: For Lithuania coverage is 0% for children. 
 
This table reports the median z-score for BMI, the mean z-score for BMI and other descriptive statistics for 
children aged 2 to 17 years, by country. 
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Table 6.9 BMI: descriptive statistics by country. All patients seen in 2014 aged 18 years or older. 
Country N N Miss Mean Min 25th pctl 
 
(25% of the 
patients are 
below  this 
BMI) 
Median 
 
(50% of the 
patients are 
below this 
BMI) 
75th pctl 
 
(75% of the 
patients are 
below this 
BMI) 
Max 
Austria 296 1 21.3 14.0 19.1 21.0 23.0 37.9 
Czech Republic 205 31 21.0 12.7 18.9 20.5 22.7 32.6 
Denmark 260 0 21.8 14.6 19.4 21.4 23.6 33.3 
France 3139 52 21.1 12.0 18.8 20.7 22.7 43.9 
Greece 202 2 21.5 15.0 19.7 21.2 23.1 31.8 
Hungary 205 5 20.3 14.3 17.9 19.8 22.4 31.1 
Ireland 343 41 22.4 13.1 20.1 21.9 24.3 35.1 
Israel 282 0 22.4 15.4 19.8 22.0 24.6 40.1 
Italy 2444 86 21.9 13.2 19.7 21.4 23.7 48.4 
Latvia <10 0 20.0 18.8 18.9 20.0 20.5 21.9 
Lithuania 12 0 19.6 15.6 17.8 20.2 21.2 23.0 
Rep of Macedonia 22 0 20.7 17.8 19.7 20.5 21.9 23.5 
Rep of Moldova 13 0 19.0 15.0 17.6 19.4 20.3 22.5 
The Netherlands 731 21 22.0 15.5 20.1 21.5 23.6 39.0 
Portugal 91 0 22.2 15.1 20.0 21.6 24.1 35.0 
Russian Federation 527 7 19.4 12.4 17.2 19.0 21.2 35.9 
Serbia 39 0 19.2 14.1 17.8 19.2 20.7 24.2 
Slovak Republic 117 0 21.0 14.7 18.6 20.7 23.3 32.5 
Slovenia 22 0 20.2 16.9 18.6 20.2 21.3 27.2 
Spain 562 11 21.9 14.5 19.8 21.6 23.4 44.3 
Sweden 379 4 22.4 13.8 20.2 21.7 24.0 36.9 
Switzerland 326 0 21.2 13.8 19.2 20.8 22.7 36.3 
Ukraine 11 0 18.4 14.1 17.6 18.5 19.3 21.8 
United Kingdom 4997 96 22.6 13.1 20.1 22.1 24.6 48.5 
 
 Note: Romania has only one adult patient and is excluded from the table. 
 
This table reports the median BMI (expressed as absolute values, not as z-scores), the mean BMI and other 
descriptive statistics for patients aged 18 years or older, by country. 
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Table 6.10   BMI: descriptive statistics by country. All male patients seen in 2014 aged 18 years or older. 
Country N N Miss Mean Min 25th pctl 
 
(25% of the 
patients are 
below  this 
BMI) 
Median 
 
(50% of the 
patients are 
below this 
BMI) 
75th pctl 
 
(75% of the 
patients are 
below this 
BMI) 
Max 
Austria 163 0 21.7 14.3 19.4 21.5 23.6 37.9 
Czech Republic 101 17 21.1 15.2 18.8 20.6 22.7 32.6 
Denmark 138 0 22.4 15.5 20.2 21.9 24.7 32.5 
France 1641 25 21.2 13.3 19.1 20.9 23.0 36.4 
Greece 104 1 21.8 15.1 19.6 21.8 23.8 31.5 
Hungary 119 4 20.8 15.5 18.4 20.5 23.1 31.1 
Ireland 213 24 22.8 16.7 20.8 22.3 24.8 33.3 
Israel 159 0 22.7 15.4 20.5 22.8 24.9 34.5 
Italy 1291 42 22.4 14.7 20.3 22.1 24.3 42.2 
Latvia <10 0 20.2 18.8 19.9 20.0 20.5 21.9 
Lithuania <10 0 20.6 18.0 20.2 20.6 21.8 23.0 
Rep of Macedonia 13 0 20.9 18.9 19.6 21.5 22.1 23.5 
Rep of Moldova <10 0 18.9 16.4 17.1 18.9 20.3 22.5 
The Netherlands 409 16 22.2 15.6 20.4 22.0 23.8 30.4 
Portugal 47 0 21.5 15.1 19.3 21.0 23.6 29.1 
Russian Federation 298 5 19.7 12.4 17.6 19.3 21.4 35.9 
Serbia 23 0 20.0 14.4 18.6 20.1 21.8 24.2 
Slovak Republic 58 0 21.5 14.7 18.9 20.9 24.3 32.5 
Slovenia 10 0 21.5 16.9 20.0 21.4 22.6 27.2 
Spain 293 5 22.4 15.2 20.3 22.2 23.9 44.3 
Sweden 197 3 23.2 16.3 20.9 22.8 25.1 35.7 
Switzerland 183 0 21.5 13.8 19.7 21.5 23.0 36.3 
Ukraine <10 0 18.2 14.1 16.4 18.6 20.0 21.8 
United Kingdom 2728 49 23.0 13.1 20.5 22.7 25.0 48.5 
 
Note: Romania has only one adult patient and is excluded from the table. 
 
This table reports the median BMI (expressed as absolute values, not as z-scores), the mean BMI and other 
descriptive statistics for male patients aged 18 years or older, by country. 
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Table 6.11  BMI: descriptive statistics by country. All female patients seen in 2014 aged 18 years or older. 
Country N N Miss Mean Min 25th pctl 
 
(25% of the 
patients are 
below  this 
BMI) 
Median 
 
(50% of the 
patients are 
below this 
BMI) 
75th pctl 
 
(75% of the 
patients are 
below this 
BMI) 
Max 
Austria 133 1 20.7 14.0 18.8 20.2 22.1 34.4 
Czech Republic 104 14 20.9 12.7 19.0 20.4 22.7 32.6 
Denmark 122 0 21.1 14.6 18.8 20.7 22.6 33.3 
France 1498 27 20.8 12.0 18.6 20.3 22.2 43.9 
Greece 98 1 21.1 15.0 19.8 20.7 22.6 31.8 
Hungary 86 1 19.7 14.3 17.5 19.2 21.1 30.1 
Ireland 130 17 21.8 13.1 19.4 21.0 23.2 35.1 
Israel 123 0 21.9 15.8 19.5 21.0 23.9 40.1 
Italy 1153 44 21.3 13.2 19.1 20.7 22.6 48.4 
Lithuania <10 0 18.1 15.6 17.7 17.8 17.8 21.8 
Rep of Macedonia <10 0 20.5 17.8 20.1 20.4 20.8 22.3 
Rep of Moldova <10 0 19.2 15.0 18.8 20.0 20.3 21.7 
The Netherlands 322 5 21.8 15.5 19.8 21.3 22.9 39.0 
Portugal 44 0 23.0 15.9 20.5 22.4 24.8 35.0 
Russian Federation 229 2 19.0 13.2 16.8 18.8 20.8 33.9 
Serbia 16 0 18.1 14.1 17.5 18.4 19.1 20.2 
Slovak Republic 59 0 20.6 14.8 18.2 20.7 22.4 27.3 
Slovenia 12 0 19.2 17.6 17.9 19.0 20.2 20.8 
Spain 269 6 21.4 14.5 19.2 20.9 22.6 40.5 
Sweden 182 1 21.5 13.8 19.8 21.0 22.6 36.9 
Switzerland 143 0 20.7 15.8 18.8 20.0 22.0 36.2 
Ukraine <10 0 18.7 18.2 18.2 18.5 19.3 19.3 
United Kingdom 2269 47 22.3 13.4 19.6 21.5 23.9 47.2 
 
 Note: Latvia and Romania are excluded from the table; Latvia has only one adult female patient, Romania has no adult 
female patients. 
 
This table reports the median BMI (expressed as absolute values, not as z-scores), the mean BMI and other 
descriptive statistics, for female patients aged 18 years or older, by country. 
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Figure 6.6 Quartiles of z-scores for BMI by age group and country. Patients aged 2-17 years in 2014. 
The figures below show the z-scores for BMI by country. The dot is the median, and the whiskers show the 
25th and 75th percentiles. In blue are the quartiles for the country, in red are the pooled quartiles computed 
on all other countries (i.e. excluding that country). We did not compute quartiles where the number of 
patients in the age group is <10. Therefore, there are no blue dots for those age groups (the number of 
patients in each age group is shown underneath the horizontal axis). We excluded Latvia and Lithuania 
from the graphs because none of the age groups in these countries had more than 10 patients. 
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[figure 6.6 continued] 
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[figure 6.6 continued] 
 
Quartiles of z-scores for BMI: Slovak Republic 
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Figure 6.7 Proportion of paediatric patients underweight (z-score of BMI<-2): age and sex pyramids, 
by country and overall. Patients aged 2-17 years in 2014. 
The coloured bars (red for females, blue for males) represent the percentage of underweight patients in 
the selected country, whereas the non-coloured bars represent the percentage of underweight patients 
in all the remaining countries (i.e. excluding that country). We excluded from the analyses those age groups 
where the number of patients was <10. We therefore excluded from the graphs Latvia, Lithuania, Republic 
of Moldova and Romania because some of the age groups in these countries had less than 10 patients. 
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[figure 6.7 continued] 
z-score of BMI <-2: Ireland z-score of BMI <-2: Israel 
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[figure 6.7 continued] 
z-score of BMI <-2: Slovak Republic z-score of BMI <-2: Slovenia 
  
 
z-score of BMI <-2: Spain 
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Figure 6.8 Proportion of adult patients with BMI<20: age and sex pyramids, by country and overall. 
Patients aged 18 years or older in 2014.  
The coloured bars (red for females, blue for males) represent the percentage of patients with BMI<20 in 
the selected country, whereas the non-coloured bars represent the percentage of patients with BMI<20 
in all the remaining countries (i.e. excluding that country). We excluded from the analyses those age groups 
where the number of patients was <10. We therefore excluded from the graphs Latvia, Lithuania, Republic 
of Moldova, Republic of Macedonia, Romania, Serbia, Slovenia and Ukraine because some of the age 
groups in these countries had less than 10 patients. 
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[figure 6.8 continued] 
BMI<20 kg/m2: Ireland BMI<20 kg/m2: Israel 
  
 
BMI<20 kg/m2: Italy 
 
BMI<20 kg/m2: The Netherlands 
  
 
BMI<20 kg/m2: Portugal 
 
BMI<20 kg/m2: Russian Federation 
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[figure 6.8 continued] 
BMI<20 kg/m2: Spain BMI<20 kg/m2: Sweden 
  
 
BMI<20 kg/m2: Switzerland 
 
BMI<20 kg/m2: Slovak Republic 
  
 
BMI<20 kg/m2: United Kingdom 
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7. Complications and therapy 
The information in this section should not be considered complete, either because national registries do 
not collect data about one or more complications, since they use a different definition or because the 
status of the complication is truly unknown (e.g. liver disease, where the definition requires ultrasound 
examination). In the tables, therefore, we show the number of missing values for the various com-
plications, but in the graphs we have included only countries where less than 10% of the data was missing. 
For a full list of complications and definitions please see Appendix 2 on page 122. 
In this section we also present data on selected therapies. We collected information on therapies using 
the generic name of the drug (i.e. not the brand name), in order to avoid data collection bias due to brand 
names. For example, we ask whether the patient has been taking ”inhaled antibiotics for more than three 
months this year”, instead of naming individual antibiotics. 
Like the complications section, the information presented in the therapy section should not be considered 
complete, and we will show only selected results, in accordance with the same criteria used for 
complications. 
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Table 7.1 Prevalence of allergic bronchopulmonary aspergillosis (all patients seen in 2014) and CFRD 
treated with insulin in 2014 (patients aged 18 years or older), by country.  
Country ABPA this year 
 
number (%) 
CF related diabetes with daily 
use of insulin this year 
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 6 655 26 4 227 84 
 (0.87) (95.34) (3.78) (1.27) (72.06) (26.67) 
Czech Republic 22 565 12 16 166 88 
 (3.67) (94.32) (2.00) (5.93) (61.48) (32.59) 
Denmark 459 0 0 0 165 108 
 (100) (0) (0) (0) (60.44) (39.56) 
France1 0 5718 651 0 2517 825 
 (0) (89.78) (10.22) (0) (75.31) (24.69) 
Greece 112 378 17 21 186 49 
 (22.09) (74.56) (3.35) (8.20) (72.66) (19.14) 
Hungary 82 473 2 51 151 47 
 (14.72) (84.92) (0.36) (20.48) (60.64) (18.88) 
Ireland 14 876 52 11 290 115 
 (1.49) (92.99) (5.52) (2.64) (69.71) (27.64) 
Israel 8 515 24 7 216 87 
 (1.46) (94.15) (4.39) (2.26) (69.68) (28.06) 
Italy 1776 3076 128 339 1809 617 
 (35.66) (61.77) (2.57) (12.26) (65.42) (22.31) 
Latvia 2 36 0 0 8 3 
 (5.26) (94.74) (0) (0) (72.73) (27.27) 
Lithuania 0 12 0 0 11 1 
 (0) (100) (0) (0) (91.67) (8.33) 
Rep of Macedonia 0 98 2 0 20 7 
 (0) (98.00) (2.00) (0) (74.07) (25.93) 
Rep of Moldova 0 60 1 0 13 1 
 (0) (98.36) (1.64) (0) (92.86) (7.14) 
The Netherlands 164 1100 114 164 378 237 
 (11.90) (79.83) (8.27) (21.05) (48.52) (30.42) 
Portugal 4 251 3 1 90 12 
 (1.55) (97.29) (1.16) (0.97) (87.38) (11.65) 
Romania 0 39 1 - - - 
 (0) (97.50) (2.50)    
Russian Federation 94 1998 29 29 552 45 
 (4.43) (94.20) (1.37) (4.63) (88.18) (7.19) 
Serbia 1 146 7 1 34 11 
 (0.65) (94.81) (4.55) (2.17) (73.91) (23.91) 
Slovak Republic 2 221 18 1 106 14 
 (0.83) (91.70) (7.47) (0.83) (87.6) (11.57) 
Slovenia 0 83 1 0 21 5 
 (0) (98.81) (1.19) (0) (80.77) (19.23) 
Spain 25 1410 46 13 422 186 
 (1.69) (95.21) (3.11) (2.09) (67.95) (29.95) 
Sweden 0 614 12 0 288 104 
 (0) (98.08) (1.92) (0) (73.47) (26.53) 
Switzerland 12 682 42 5 265 84 
 (1.63) (92.66) (5.71) (1.41) (74.86) (23.73) 
Ukraine 2 104 1 0 12 1 
 (1.87) (97.20) (0.93) (0) (92.31) (7.69) 
United Kingdom 0 8413 1017 0 3454 1757 
 (0) (89.22) (10.78) (0) (66.28) (33.72) 
1 France: ABPA was collected as: Aspergillosis (ABPA and other) if treated. 
 Note: Romania has only one adult patient and therefore no information is included for CFRD. 
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Table 7.1 shows the frequency of allergic bronchopulmonary aspergillosis (see Appendix 2, page 122, for 
ABPA definitions) and CF-related diabetes (CFRD), defined here as treated daily with insulin,  by country. 
For CFRD only patients 18 years or older are included. 
 
Figure 7.1 Prevalence of allergic bronchopulmonary aspergillosis in all patients seen in 2014, by country.  
 
Note: We excluded from the graph the countries for which the information on allergic bronchopulmonary 
           aspergillosis (ABPA) was missing for more than 10% of the patients.  
Note: France collected ABPA as Aspergillosis (ABPA and other) if treated. 
 
 
This graph shows the frequency of allergic bronchopulmonary aspergillosis by country. For the definition 
of ABPA see Appendix 2 (page 122). The dark green part of the bar shows the percentage of patients with 
ABPA, the light green part shows the percentage of patients for which this information was missing. 
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Figure 7.2 Prevalence of CFRD requiring daily insulin treatment, by country. All patients seen in 2014 
aged 18 years or older. 
 
Note: We excluded from the graph the countries for which the information on CFRD was missing for more than 
 10% of the patients. Romania has one adult patient and is excluded from the graph. 
 
 
This graph shows the prevalence of CF-related diabetes (CFRD) by country. CFRD is recorded differently 
among the national registries. As a substitute marker of diabetes we have collected data on the use of 
insulin on a daily basis. The dark green part of the bar shows the percentage of patients who use insulin 
daily, the light green part shows the percentage of patients for whom this information was missing. Only 
patients aged 18 years or older were included in this graph. 
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Table 7.2 Prevalence of pneumothorax, haemoptysis and malignancy in all patients seen in 2014, by 
country.  
Country Pneumothorax requiring chest 
tube this year 
number (%) 
Haemoptysis major over 250 ml 
this year 
number (%) 
Malignancy occurred this year 
 
number(%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 4 680 3 20 646 21 7 677 3 
 (0.58) (98.98) (0.44) (2.91) (94.03) (3.06) (1.02) (98.54) (0.44) 
Czech Republic 22 571 6 23 571 5 22 577 0 
 (3.67) (95.33) (1.00) (3.84) (95.33) (0.83) (3.67) (96.33) (0) 
Denmark 0 457 2 459 0 0 0 458 1 
 (0) (99.56) (0.44) (100) (0) (0) (0) (99.78) (0.22) 
France1 0 6328 41 0 6053 316 0 6343 26 
 (0) (99.36) (0.64) (0) (95.04) (4.96) (0) (99.59) (0.41) 
Greece 94 407 6 96 401 10 95 412 0 
 (18.54) (80.28) (1.18) (18.93) (79.09) (1.97) (18.74) (81.26) (0) 
Hungary 92 456 9 124 424 9 112 442 3 
 (16.52) (81.87) (1.62) (22.26) (76.12) (1.62) (20.11) (79.35) (0.54) 
Ireland 14 922 6 14 927 <5 14 924 <5 
 (1.49) (97.88) (0.64) (1.49) (98.41) (0.11) (1.49) (98.09) (0.42) 
Israel 10 533 4 9 519 19 11 536 0 
 (1.83) (97.44) (0.73) (1.65) (94.88) (3.47) (2.01) (97.99) (0) 
Italy 967 4001 12 974 3953 53 969 3993 18 
 (19.42) (80.34) (0.24) (19.56) (79.38) (1.06) (19.46) (80.18) (0.36) 
Latvia 1 37 0 1 37 0 1 37 0 
 (2.63) (97.37) (0) (2.63) (97.37) (0) (2.63) (97.37) (0) 
Lithuania 0 12 0 0 12 0 0 12 0 
 (0) (100) (0) (0) (100) (0) (0) (100) (0) 
Rep of Macedonia 0 100 0 0 97 3 0 100 0 
 (0) (100) (0) (0) (97.00 (3.00) (0) (100) (0) 
Rep of Moldova 0 61 0 0 56 5 0 60 1 
 (0) (100) (0) (0) (91.80) (8.20) (0) (98.36) (1.64) 
The Netherlands2 171 1201 6 171 1146 61 0 1368 10 
 (12.41) (87.16) (0.44) (12.41) (83.16) (4.43) (0) (99.27) (0.73) 
Portugal 3 255 0 6 236 16 3 255 0 
 (1.16) (98.84) (0) (2.33) (91.47) (6.20) (1.16) (98.84) (0) 
Romania 0 40 0 0 39 1 0 40 0 
 (0) (100) (0) (0) (97.50) (2.50) (0) (100) (0) 
Russian Federation 56 2048 17 69 2026 26 57 2059 5 
 (2.64) (96.56) (0.80) (3.25) (95.52) (1.23) (2.69) (97.08) (0.24) 
Serbia 1 153 0 1 148 5 1 153 0 
 (0.65) (99.35) (0) (0.65) (96.1) (3.25) (0.65) (99.35) (0) 
Slovak Republic 2 239 0 3 217 21 2 239 0 
 (0.83) (99.17) (0) (1.24) (90.04) (8.71) (0.83) (99.17) (0) 
Slovenia 0 84 0 0 84 0 0 84 0 
 (0) (100) (0) (0) (100) (0) (0) (100) (0) 
Spain 26 1449 6 28 1383 70 25 1442 14 
 (1.76) (97.84) (0.41) (1.89) (93.38) (4.73) (1.69) (97.37) (0.95) 
Sweden 0 623 3 0 626 0 0 622 4 
 (0) (99.52) (0.48) (0) (100) (0) (0) (99.36) (0.64) 
Switzerland 9 725 2 13 692 31 8 725 3 
 (1.22) (98.51) (0.27) (1.77) (94.02) (4.21) (1.09) (98.51) (0.41) 
Ukraine 2 104 1 2 103 2 2 105 0 
 (1.87) (97.2) (0.93) (1.87) (96.26) (1.87) (1.87) (98.13) (0) 
United Kingdom 0 9363 67 0 9395 35 0 9397 33 
 (0) (99.29) (0.71) (0) (99.63) (0.37) (0) (99.65) (0.35) 
 
1 France: pneumothorax only; haemoptysis, no quantification. 
2 The Netherlands: malignancy diagnosed this year or in the past.  
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Table 7.2, previous page, shows the frequency of three rare complications: Pneumothorax (collapsed 
lung) requiring chest tube, haemoptysis (coughing up of blood) of more than 250 ml and occurrence of 
malignancy (cancer). All these complications are extremely rare. 
 Table 7.3 Prevalence of liver disease and use of ursodeoxycholic acid in all patients seen in 2014, by 
country.  
Country Liver disease this year 
 
number (%) 
Ursodeoxycholic acid  
this year 
number (%) 
Missing/ 
unknown 
No 
liver 
disease 
Cirrhosis Liver 
disease 
without 
cirrhosis 
Missing/ 
unknown 
No Yes 
Cirrhosis with  
portal 
hypertension/ 
hypersplenism 
Cirrhosis no  
portal 
hypertension/ 
hypersplenism 
Cirrhosis, 
portal 
hypertensio
n unknown 
Austria 9 421 42 13 2 200 5 348 334 
 (1.31) (61.28) (6.11) (1.89) (0.29) (29.11) (0.73) (50.66) (48.62) 
Czech Republic 193 252 5 11 0 138 22 360 217 
 (32.22) (42.07) (0.83) (1.84) (0) (23.04) (3.67) (60.10) (36.23) 
Denmark 35 368 6 3 15 32 0 352 107 
 (7.63) (80.17) (1.31) (0.65) (3.27) (6.97) (0) (76.69) (23.31) 
France1 0 6097 0 0 272 0 0 4287 2082 
 (0) (95.73) (0) (0) (4.27) (0) (0) (67.31) (32.69) 
Greece 103 309 33 9 9 44 94 311 102 
 (20.32) (60.95) (6.51) (1.78) (1.78) (8.68) (18.54) (61.34) (20.12) 
Hungary 91 315 63 11 53 24 60 305 192 
 (16.34) (56.55) (11.31) (1.97) (9.52) (4.31) (10.77) (54.76) (34.47) 
Ireland2 14 808 34 <5 <5 83 14 827 101 
 (1.49) (85.77) (3.61) (0.11) (0.21) (8.81) (1.49) (87.79) (10.72) 
Israel 10 444 18 4 0 71 6 436 105 
 (1.83) (81.17) (3.29) (0.73) (0) (12.98) (1.10) (79.71) (19.2) 
Italy 968 2978 50 49 4 931 976 2551 1453 
 (19.44) (59.80) (1.00) (0.98) (0.08) (18.69) (19.60) (51.22) (29.18) 
Latvia 1 13 1 0 0 23 1 16 21 
 (2.63) (34.21) (2.63) (0) (0) (60.53) (2.63) (42.11) (55.26) 
Lithuania 0 12 0 0 0 0 0 12 0 
 (0) (100) (0) (0) (0) (0) (0) (100) (0) 
Rep of Macedonia 0 50 4 15 0 31 0 50 50 
 (0) (50.00) (4.00) (15.00) (0) (31.00) (0) (50.00) (50.00) 
Rep of Moldova 0 60 1 0 0 0 0 0 61 
 (0) (98.36) (1.64) (0) (0) (0) (0) (0) (100) 
The Netherlands 190 939 64 20 163 2 5 989 384 
 (13.79) (68.14) (4.64) (1.45) (11.83) (0.15) (0.36) (71.77) (27.87) 
Portugal 7 196 3 0 0 52 1 179 78 
 (2.71) (75.97) (1.16) (0) (0) (20.16) (0.39) (69.38) (30.23) 
Romania 0 34 0 0 0 6 0 37 3 
 (0) (85.00) (0) (0) (0) (15.00) (0) (92.50) (7.50) 
Russian Federation 74 1443 78 80 4 442 54 178 1889 
 (3.49) (68.03) (3.68) (3.77) (0.19) (20.84) (2.55) (8.39) (89.06) 
 
1 France: collects cirrhosis/liver disease yes or no – these have been pooled under cirrhosis, portal hypertension 
unknown. 
2  Ireland: when the number of patients is less than 5 the information is suppressed.   
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[table 7.3 continued] 
Country Liver disease this year 
 
number (%) 
Ursodeoxycholic acid  
this year 
number (%) 
Missing/ 
unknown 
No 
liver 
disease 
Cirrhosis Liver 
disease 
without 
cirrhosis 
Missing/ 
unknown 
No Yes 
Cirrhosis with  
portal 
hypertension/ 
hypersplenism 
Cirrhosis no  
portal 
hypertension/ 
hypersplenism 
Cirrhosis, 
portal 
hypertensio
n unknown 
Serbia¹ 2 98 8 5 1 40 1 99 54 
 (1.3) (63.64) (5.19) (3.25) (0.65) (25.97) (0.65) (64.29) (35.06) 
Slovak Republic 3 122 7 8 1 100 2 126 113 
 (1.24) (50.62) (2.90) (3.32) (0.41) (41.49) (0.83) (52.28) (46.89) 
Slovenia 0 59 1 0 0 24 1 33 50 
 (0) (70.24) (1.19) (0) (0) (28.57) (1.19) (39.29) (59.52) 
Spain 26 1122 16 3 1 313 27 1102 352 
 (1.76) (75.76) (1.08) (0.20) (0.07) (21.13) (1.82) (74.41) (23.77) 
Sweden² 1 498 8 8 0 111 23 463 140 
 (0.16) (79.55) (1.28) (1.28) (0) (17.73) (3.67) (73.96) (22.36) 
Switzerland 38 529 25 15 3 126 9 508 219 
 (5.16) (71.88) (3.40) (2.04) (0.41) (17.12) (1.22) (69.02) (29.76) 
Ukraine 2 23 3 5 5 69 3 3 101 
 (1.87) (21.50) (2.80) (4.67) (4.67) (64.49) (2.80) (2.80) (94.39) 
United Kingdom 0 7889 158 126 0 1257 107 7367 1956 
 (0) (83.66) (1.68) (1.34) (0) (13.33) (1.13) (78.12) (20.74) 
 
¹  Serbia: cirrhosis without portal hypertension/hypersplenism means the presence of CF-related liver disease with 
normal liver function. 
²  Sweden: has only collected cirrhosis with portal hypertension yes or no this year. The rest have been set to No liver 
disease due to software issues. The prevalence of use of ursodeoxycholic acid could be used as an indicator of the 
total prevalence of liver disease of all categories. 
 
This table shows the frequency and severity of liver disease according to the ECFSPR definitions (see 
Appendix 2, page 122) and use of ursodeoxycholic acid, a commonly used treatment for CF liver disease. 
The frequency and severity of liver disease differs greatly, and does not correspond to the number of 
patients on ursodeoxycholic acid. 
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Figure 7.3 Prevalence and severity of liver disease in all patients seen in 2014, by country.  
 
 
Note:  We excluded from the graph the countries for which the information on liver disease was missing for more 
            than 10% of the patients. 
Note:  France: collects cirrhosis/liver disease yes or no – these have been pooled under cirrhosis, portal hyper-
tension unknown. 
Serbia: cirrhosis without portal hypertension/hypersplenism means the presence of CF-related disease with 
normal liver function. 
Sweden: has only collected cirrhosis with portal hypertension yes or no this year. The rest have been set to 
No liver disease due to software issues. The prevalence of use of ursodeoxycholic acid could be used as an 
indicator of the total amount of liver disease of all categories. 
 
 
This graph shows the frequency of liver disease by country. Liver disease is defined according to severity 
of portal hypertension (increased blood pressure in the liver veins, often resulting in blood shunting past 
the cirrhotic liver), divided into five categories, including no liver disease (see Appendix 2, page 122). This 
graph emphasises better than the table the vast differences in frequency and severity, which may be due 
to problems in definitions and diagnostic tools.  
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Figure 7.4 Use of ursodeoxycholic acid in all patients seen in 2014, by country.  
 
 
Note: We excluded from the graph the countries for which the information on ursodeoxycholic acid was missing 
           for more than 10% of the patients. 
 
 
This graph shows how many patients used ursodeoxycholic acid during the survey year. Ursodeoxycholic 
acid is used as a treatment for CF liver disease. The dark green part of the bar indicates the percentage of 
patients taking this drug, the light green part shows the percentage of patients for whom this information 
is missing.  
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Table 7.4   Use of hypertonic saline, rhDNase and bronchodilators in all patients seen in 2014, by country. 
Country Hypertonic saline (NaCl)  
inhaled > 3 months this year 
number (%) 
rhDNase 
 inhaled > 3 months this year  
number (%) 
Bronchodilators 
inhaled > 3 months this year  
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 7 345 335 7 331 349 6 89 592 
 (1.02) (50.22) (48.76) (1.02) (48.18) (50.80) (0.87) (12.95) (86.17) 
Czech Republic 22 404 173 22 226 351 22 282 295 
 (3.67) (67.45) (28.88) (3.67) (37.73) (58.60) (3.67) (47.08) (49.25) 
Denmark 459 0 0 0 60 399 459 0 0 
 (100) (0) (0) (0) (13.07) (86.93) (100) (0) (0) 
France 0 5981 388 0 3263 3106 0 3183 3186 
 (0) (93.91) (6.09) (0) (51.23) (48.77) (0) (49.98) (50.02) 
Greece 92 310 105 95 200 212 92 221 194 
 (18.15) (61.14) (20.71) (18.74) (39.45) (41.81) (18.15) (43.59) (38.26) 
Hungary 74 164 319 66 230 261 75 214 268 
 (13.29) (29.44) (57.27) (11.85) (41.29) (46.86) (13.46) (38.42) (48.11) 
Ireland 14 442 486 14 299 629 14 326 602 
 (1.49) (46.92) (51.59) (1.49) (31.74) (66.77) (1.49) (34.61) (63.91) 
Israel 4 188 355 7 189 351 5 194 348 
 (0.73) (34.37) (64.90) (1.28) (34.55) (64.17) (0.91) (35.47) (63.62) 
Italy 1718 2029 1233 979 2721 1280 1714 963 2303 
 (34.50) (40.74) (24.76) (19.66) (54.64) (25.70) (34.42) (19.34) (46.24) 
Latvia 1 2 35 1 7 30 1 3 34 
 (2.63) (5.26) (92.11) (2.63) (18.42) (78.95) (2.63) (7.89) (89.47) 
Lithuania 0 11 1 0 0 12 0 1 11 
 (0) (91.67) (8.33) (0) (0) (100) (0) (8.33) (91.67) 
Rep of Macedonia 1 71 28 0 29 71 0 4 96 
 (1.00) (71.00) (28.00) (0) (29.00) (71.00) (0) (4.00) (96.00) 
Rep of Moldova 0 0 61 0 61 0 0 0 61 
 (0) (0) (100) (0) (100) (0) (0) (0) (100) 
The Netherlands 8 1002 368 6 552 820 5 770 603 
 (0.58) (72.71) (26.71) (0.44) (40.06) (59.51) (0.36) (55.88) (43.76) 
Portugal 2 207 49 4 69 185 2 134 122 
 (0.78) (80.23) (18.99) (1.55) (26.74) (71.71) (0.78) (51.94) (47.29) 
Romania 0 5 35 0 12 28 0 5 35 
 (0) (12.50) (87.50) (0) (30.00) (70.00) (0) (12.50) (87.50) 
Russian Federation 64 1110 947 44 142 1935 71 693 1357 
 (3.02) (52.33) (44.65) (2.07) (6.69) (91.23) (3.35) (32.67) (63.98) 
Serbia 1 18 135 1 82 71 1 1 152 
 (0.65) (11.69) (87.66) (0.65) (53.25) (46.10) (0.65) (0.65) (98.70) 
Slovak Republic 2 221 18 2 90 149 4 113 124 
 (0.83) (91.70) (7.47) (0.83) (37.34) (61.83) (1.66) (46.89) (51.45) 
Slovenia 1 3 80 0 53 31 2 71 11 
 (1.19) (3.57) (95.24) (0) (63.10) (36.90) (2.38) (84.52) (13.10) 
Spain 27 608 846 26 1175 280 26 418 1037 
 (1.82) (41.05) (57.12) (1.76) (79.34) (18.91) (1.76) (28.22) (70.02) 
Sweden 25 195 406 25 462 139 24 65 537 
 (3.99) (31.15) (64.86) (3.99) (73.80) (22.20) (3.83) (10.38) (85.78) 
Switzerland 8 280 448 6 449 281 8 75 653 
 (1.09) (38.04) (60.87) (0.82) (61.01) (38.18) (1.09) (10.19) (88.72) 
Ukraine 3 1 103 9 66 32 3 35 69 
 (2.80) (0.93) (96.26) (8.41) (61.68) (29.91) (2.80) (32.71) (64.49) 
United Kingdom1 0 6964 2466 0 4288 5142 0 4483 4947 
 (0) (73.85) (26.15) (0) (45.47) (54.53) (0) (47.54) (52.46) 
 
1 United Kingdom: the duration of use of inhaled hypertonic saline and of bronchodilators is not specified. 
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Table 7.4 shows the use of three different inhaled medications: hypertonic saline, rhDNase (Pulmozyme®) 
and bronchodilators (see page 14 for abbreviations). All of these medications are widely used, but still with 
marked differences among the countries. 
 
Figure 7.5 Use of inhaled hypertonic saline in all patients seen in 2014, by country.  
 
 
Note: We excluded from the graph the countries for which the information on inhaled hypertonic saline was 
           missing for more than 10% of the patients. 
Note: United Kingdom: the duration of use of inhaled hypertonic saline is not specified. 
 
 
This table shows the use of inhaled hypertonic saline for more than three months during the survey year. 
The dark green part of the bar indicates the percentage of patients taking the medication, the light green 
part shows the percentage of patients for whom this information is missing. 
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Figure 7.6 Use of rhDNase in all patients seen in 2014, by country.  
 
 
Note:  We excluded from the graph the countries for which the information on rhDNase was missing for more 
than 10% of the patients. 
 
 
This graph shows the use of rhDNase (marketed as Pulmozyme®) as inhalations for more than three 
months during the survey year. The dark green part of the bar indicates the percentage of patients taking 
this drug, the light green part shows the percentage of patients for whom this information is missing. 
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Figure 7.7  Use of bronchodilators in all patients seen in 2014, by country.  
 
 
Note:  We excluded from the graph the countries for which the information on use of bronchodilators was missing 
            for more than 10% of the patients. 
Note:  United Kingdom: the duration of use of bronchodilators is not specified. 
 
 
This graph shows the use of bronchodilators for more than three months during the survey year. This is 
the most widely used inhaled medication, but still there are large differences in frequency of use between 
countries. The dark green part of the bar indicates the percentage of patients taking these drug, the light 
green part shows the percentage of patients for whom this information is missing.  
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Table 7.5 Use of inhaled antibiotics, macrolides and oxygen in all patients seen in 2014, by country.  
Country Inhaled antibiotics 
inhaled > 3 months this year 
number (%) 
Oxygen therapy 
this year  
number (%) 
Macrolides 
> 3 months this year  
number (%) 
Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes Missing/ 
unknown 
No Yes 
Austria 8 433 246 6 648 33 6 609 72 
 (1.16) (63.03) (35.81) (0.87) (94.32) (4.80) (0.87) (88.65) (10.48) 
Czech Republic 22 412 165 22 554 23 22 488 89 
 (3.67) (68.78) (27.55) (3.67) (92.49) (3.84) (3.67) (81.47) (14.86) 
Denmark 459 0 0 459 0 0 459 0 0 
 (100) (0) (0) (100) (0) (0) (100) (0) (0) 
France1 0 3764 2605 0 6072 297 0 3559 2810 
 (0) (59.10) (40.90) (0) (95.34) (4.66) (0) (55.88) (44.12) 
Greece 91 169 247 91 396 20 93 339 75 
 (17.95) (33.33) (48.72) (17.95) (78.11) (3.94) (18.34) (66.86) (14.79) 
Hungary 74 278 205 66 442 49 59 360 138 
 (13.29) (49.91) (36.80) (11.85) (79.35) (8.80) (10.59) (64.63) (24.78) 
Ireland 109 434 399 14 881 47 63 478 401 
 (11.57) (46.07) (42.36) (1.49) (93.52) (4.99) (6.69) (50.74) (42.57) 
Israel 5 248 294 5 530 12 7 249 291 
 (0.91) (45.34) (53.75) (0.91) (96.89) (2.19) (1.28) (45.52) (53.20) 
Italy 977 2564 1439 976 3765 239 976 2668 1336 
 (19.62) (51.49) (28.90) (19.60) (75.60) (4.80) (19.60) (53.57) (26.83) 
Latvia 1 12 25 1 33 4 1 26 11 
 (2.63) (31.58) (65.79) (2.63) (86.84) (10.53) (2.63) (68.42) (28.95) 
Lithuania 0 11 1 0 10 2 0 12 0 
 (0) (91.67) (8.33) (0) (83.33) (16.67) (0) (100) (0) 
Rep of Macedonia 0 56 44 0 98 2 0 77 23 
 (0) (56.00) (44.00) (0) (98.00) (2.00) (0) (77.00) (23.00) 
Rep of Moldova 0 28 33 0 59 2 0 23 38 
 (0) (45.90) (54.10) (0) (96.72) (3.28) (0) (37.70) (62.30) 
The Netherlands 5 719 654 5 1315 58 5 716 657 
 (0.36) (52.18) (47.46) (0.36) (95.43) (4.21) (0.36) (51.96) (47.68) 
Portugal 1 122 135 1 239 18 3 150 105 
 (0.39) (47.29) (52.33) (0.39) (92.64) (6.98) (1.16) (58.14) (40.70) 
Romania 0 21 19 0 39 1 0 36 4 
 (0) (52.50) (47.50) (0) (97.50) (2.50) (0) (90.00) (10.00) 
Russian Federation 61 1206 854 61 1964 96 60 1393 668 
 (2.88) (56.86) (40.26) (2.88) (92.60) (4.53) (2.83) (65.68) (31.49) 
Serbia 1 84 69 1 148 5 1 137 16 
 (0.65) (54.55) (44.81) (0.65) (96.10) (3.25) (0.65) (88.96) (10.39) 
Slovak Republic 1 119 121 1 235 5 1 163 77 
 (0.41) (49.38) (50.21) (0.41) (97.51) (2.07) (0.41) (67.63) (31.95) 
Slovenia 2 75 7 0 82 2 1 79 4 
 (2.38) (89.29) (8.33) (0) (97.62) (2.38) (1.19) (94.05) (4.76) 
Spain 27 678 776 27 1399 55 28 890 563 
 (1.82) (45.78) (52.40) (1.82) (94.46) (3.71) (1.89) (60.09) (38.01) 
Sweden 37 528 61 23 591 12 22 397 207 
 (5.91) (84.35) (9.74) (3.67) (94.41) (1.92) (3.51) (63.42) (33.07) 
Switzerland 13 468 255 6 705 25 5 523 208 
 (1.77) (63.59) (34.65) (0.82) (95.79) (3.40) (0.68) (71.06) (28.26) 
Ukraine 3 67 37 4 101 2 3 8 96 
 (2.80) (62.62) (34.58) (3.74) (94.39) (1.87) (2.80) (7.48) (89.72) 
United Kingdom2 0 4259 5171 38 8699 693 0 5522 3908 
 (0) (45.16) (54.84) (0.40) (92.25) (7.35) (0) (58.56) (41.44) 
 
1 France: collects only use of azithromycin. 
2 United Kingdom: the duration of use of macrolides is not specified. 
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Table 7.5 shows the use of three treatments: inhaled antibiotics for more than three months during the 
survey year (any kind); macrolides (e.g. azithromycin) for more than three months; oxygen for home 
treatment. Both inhaled antibiotics and macrolides are frequently used but with marked differences 
between countries. Oxygen is used less frequently (severe lung disease). 
 
Figure 7.8  Use of inhaled antibiotics in all patients seen in 2014, by country.  
 
 
Note:  We excluded from the graph the countries for which the information on inhaled antibiotics was missing for 
more than 10% of the patients. 
 
 
This graph shows the use of inhaled antibiotics (of any kind) for more than three months during the survey 
year. The frequency varies considerably, from 8 to 65%. The dark green part of the bar shows the 
percentage of patients taking these drug, the light green part shows the percentage of patients for whom 
this information is missing. 
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Figure 7.9  Use of macrolides in all patients seen in 2014, by country.  
 
 
Note: We excluded from the graph the countries for which the information on use of macrolides was missing for 
           more than 10% of the patients. 
Note:  France: collects only use of azithromycin for macrolides.  
           United Kingdom: the duration of use of macrolides is not specified. 
 
 
This graph shows the use of macrolides for more than three months during the survey year (e.g. 
azithromycin). Macrolides are antibiotics, but taken continuously they also modulate the immune system. 
The dark green part of the bar indicates the percentage of patients taking these drug, the light green part 
shows the percentage of patients for whom this information is missing. 
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Figure 7.10  Use of oxygen in all patients seen in 2014, by country.  
 
 
Note:  We excluded from the graph the countries for which the information on the use of oxygen was missing for 
more than 10% of the patients. 
 
 
This graph shows the use of oxygen at home during the survey year. Oxygen is used for severe lung disease. 
The dark green part of the bar indicates the percentage of patients using oxygen supplemen-tation, the 
light green part shows the percentage of patients for whom this information is missing.  
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8. Transplantation 
We ask the countries if their patients have had a lung and/or liver transplantation, and in which year they 
had their (latest) transplant. 
In some countries not all transplanted patients are in the CF centres’ database or the CF national registry, 
because the patients have been transferred to a transplant centre. For this reason, the figures below may 
report a lower number of patients with a transplant than the true number, but it has not been possible to 
acquire more accurate data. 
Table 8.1  Number of patients living in 2014 with transplanted lungs, by age and sex. 
Age Males Females Total Transplants performed during 
the survey year 
5-9 0 1 1 0 
10-14 11 11 22 9 
15-19 27 45 72 25 
20-24 84 117 201 50 
25-29 151 153 304 59 
30-34 160 166 326 27 
35-39 146 142 288 21 
40-44 130 108 238 18 
45+ 151 98 249 20 
Total 860 841 1701 229 
 
This table shows the number of patients alive in 2014 who have had a lung transplant at some time in their 
life, by age group, as well as the number of patients who have had a lung transplant during 2014. 
 
Table 8.2  Number of patients living in 2014 with transplanted liver, by age and sex. 
Age Males Females Total Transplants performed during 
the survey year 
5-9 3 1 4 0 
10-14 5 5 10 4 
15-19 16 8 24 7 
20-24 22 11 33 1 
25-29 19 13 32 1 
30-34 19 10 29 1 
35-39 12 2 14 0 
40-44 8 8 16 1 
45+ 5 2 7 1 
Total 109 60 169 16 
 
This table shows the number of patients alive in 2014 who have had a liver transplant at some time in their 
life, by age group, as well as the number of patients who have had a liver transplant during 2014. 
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Figure 8.1  Number of patients living in 2014 with transplanted lungs, by country. 
 
 
 
This graph shows the number of patients alive in 2014 who have had a lung transplant (orange bars) at 
some point in their life. The red dots (right axis) show the percentage of patients living with transplanted 
lungs in 2014 among the patients that were seen in 2014.  
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Figure 8.2  Number of patients living in 2014 with transplanted liver, by country. 
 
 
  
 
This graph shows the number of patients alive in 2014 who have had a liver transplant (green bars) at some 
point in their life. The dark green dots (right axis) show the percentage of patients that are living with a 
transplanted liver in 2014 among the patients that were seen in 2014. 
 
Note that on the vertical axis the number of patients with liver transplant is much lower than the number 
with lung transplant. The main reason for this is that liver disease is only found in a subset of CF patients, 
whereas lung disease affects almost all patients.  
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9. Mortality 
Table 9.1  Number of deaths in 2014, by age and sex. 
Age at 
death 
Number of male 
patients 
% of deaths in 
this age group of 
all male deaths 
Number of 
female patients 
% of deaths in 
this age group of 
all female deaths 
Total % Total 
0-5 10 5.49 10 4.93 20 5.19 
6-10 4 2.20 8 3.94 12 3.12 
11-20 26 14.29 42 20.69 68 17.66 
21-30 60 32.97 67 33.00 127 32.99 
31-40 47 25.82 39 19.21 86 22.34 
41-50 24 13.19 25 12.32 49 12.73 
51+ 11 6.04 12 5.91 23 5.97 
Total 182 100 203 100 385 100 
 
Note: Only patients seen during the year are presented. Belgian 2013 data (N=1,153) is excluded. For the United 
Kingdom, all seen patients with confirmed diagnosis of CF are included (N=10,580). The total number of 
patients presented is 33,664. 
Note:  For 1 male patient date at death, and therefore age at death, is unknown. 
 
This table shows the number of deaths in 2014 by age group and sex. Death in young children is very rare, 
and the most frequent age-range for death in both sexes is 21-30 years. 
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Figure 9.1 Age at death distribution of patients deceased in 2014, by sex. 
 
Note: Only patients seen during the year are presented. Belgian 2013 data (N=1,153) is excluded. For the 
United Kingdom, all seen patients with confirmed diagnosis of CF are included (N=10,580). The total 
number of patients presented is 33,664. 
Note:  For 1 male patient date at death, and therefore age at death, was unknown. 
 
 
This graph shows the distribution of age at death of patients who died in 2014, separately by males 
(yellow) and females (red). 
 
Table 9.2 Cause of death distribution in 2014. 
Cause of death Number of deaths Percentage of all deaths 
Respiratory disease 243 62.95 
Transplantation related 79 20.47 
Non-CF related 22 5.70 
Liver-GI related 4 1.04 
Suicide 0 0.00 
Trauma 1 0.26 
Unknown 37 9.59 
Total 386 100 
 
  Note: Ireland and  United Kingdom collect cause of death “respiratory disease” as “cardio/ 
respiratory”. 
 
This table shows cause of death for the deceased patients. The most frequent cause of death is respiratory 
disease. Please note that only a limited number of causes of death are collected, therefore if some deaths 
are due to rare complications of CF, they may have been classified as “Unknown”.  
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Publications 
The ECFSPR data has been actively used for research in the period 2011–2015. We received 38 applications 
for data in total. The data applications are handled in accordance with the ECFSPR guidelines 
(www.ecfs.eu/projects/efcs-patient-registry/guidelines) and reviewed conscientiously by the Scientific 
Committee.  
Several of the research projects have resulted in publications, and for some of the other projects 
manuscripts are in the pipeline. For an overview of the published articles we refer you to the webpage 
www.ecfs.eu/projects/ecfs-patient-registry/articles.  
An overview of the approved applications for data from 2011 to 2015 for which there is no publication, 
can be found on the webpage www.ecfs.eu/projects/ecfs-patient-registry/overview-data-applications. 
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Appendix 1: Technical notes 
Patient inclusion criteria 
The ECFSPR registers patients diagnosed with CF in accordance with agreed definitions (see Appendix 2). 
Data of patients with a diagnosis that does not meet the agreed definitions are accepted in the database 
but not included in the analyses. 
Data manipulation 
To ensure that data was anonymous, we collected only year and month of birth and the day of birth was 
set to the 15th of the month (for Belgium, which only supplies year of birth for adults, month of birth was 
set to 7). 
Unknown dates of lung function tests and of height/weight measurements were set to July 1st of the survey 
year. 
For pre-natal diagnoses we set age at diagnosis equal to 0. 
We checked for outliers and, whenever possible, we corrected the values according to instructions from 
the national registries/individual centres. If, after the data quality controls, aberrant values were still 
present in the database, we set them to missing for the purposes of this report. 
Reference populations used for computing z-scores 
The value of a z-score depends on the reference anthropometric chart: if different reference values are 
used, the same value of height (or weight or BMI) will result in different values of z-scores, and these 
differences could be of clinical importance. To compare the nutritional status of CF patients with that of 
healthy individuals an appropriate reference population must be used: ideally, a fair comparison requires 
that CF patients and healthy individuals belong to the same population. This implies the availability of a 
national reference. 
The lack of a national reference for most countries participating in the ECFSPR obliged us to use an inter-
national reference to compute z-scores for height, weight and BMI. We decided to use the CDC 2000 
reference charts (Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the United States: 
Methods and Development. National Centre for Health Statistics. Vital Health Stat 2002; 11(246):1-190.), 
which were derived from samples of U.S. healthy individuals1. The choice of CDC charts as a reference, 
although not the most suitable to assess the nutritional status of European CF patients, is justified by the 
widespread use of these charts at international level. 
Reference populations used for computing FEV1 predicted values 
We computed the percent of predicted values for FEV1 and FVC using: 
The multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 
equations. Eur Respir J 2012; 40: 1324–1343). 
In the addendum this year we have included the computations, as in previous reports, based on the 
references: 
 for male children (6-17 years) and female children (6-15 years): 
Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of 
age. Pediatr Pulmonol 1993; 15:75-88. 
 
 
1 For details on the target population, please see www.cdc.gov/growthcharts/2000growthchart-us.pdf.  
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
121 
 
  
 for male adults (≥18 years) and female adults (≥16 years): 
Hankinson JL, Odencrantz RJ, Fedan KB. Spirometric reference values from a sample of the general 
U.S. population. Am J Respr Crit Care Med 1999; 159:179-87. 
Software used for data management and statistical analyses 
SAS software, Version 9.4. Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or 
service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. 
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Appendix 2: List of variables, inclusion criteria and 
definitions used by the ECFSPR 
List of variables 
Demographics  Therapy 
CF centre code 
Patient code 
Year of follow-up 
Date of birth (year and month) 
Gender 
Status of patient 
Cause of death 
Date of death 
 Inhaled continuous hypertonic NaCl this year 
Inhaled continuous antibiotic this year 
Inhaled continuous bronchodilators this year 
In Oxygen therapy this year 
Use of rhDNase this year 
Use of continuous azithromycin (or other macrolide) 
this year 
Use of ursodeoxycholic acid this year 
Use of pancreatic enzymes this year 
Diagnosis  Complications 
Diagnosis confirmed 
Age at diagnosis 
Type of sweat test 
Electrolytes 
Chloride value 
Meconium Ileus 
Neonatal screening 
 Allergic bronchopulmonary aspergillosis this year 
Diabetes: daily insulin treated this year 
Pneumothorax requiring chest drain this year 
Liver disease this year 
Haemoptysis major over 250 ml this year 
Pancreatic status: faecal elastase 
Pancreatic status: faecal fat 
Occurrence of malignancy this year 
Genotype  Microbiology 
First mutation 
Second mutation 
 
 Chronic Burkholderia cepacia complex 
Nontuberculous mycobacteria this year 
Chronic Pseudomonas aeruginosa 
Chronic Staphylococcus aureus 
Stenotrophomonas maltophilia this year 
Follow-up  Transplant 
Date of best FEV1 recorded this year 
Value of best FEV1 recorded this year 
Value of best FVC recorded this year 
Height measured at date of best FEV1 (or in case 
of no FEV1 last height of the year) 
Weight measured at date of best FEV1 (or in case 
of no FEV1 last height of the year) 
 Liver transplant 
Year of latest liver transplant (if occurred before or 
during this year) 
Lung transplant 
Year of latest lung transplant (if occurred before or 
during this year) 
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Inclusion criteria 
Only patients who fulfil the diagnostic criteria below should be included in the registry. 
a. Two sweat tests value > 60 mmol/L chloride: CF diagnosis accepted 
b. One sweat test value > 60 mmol/L chloride and DNA Analysis/Genotyping – two identified disease 
causing CF mutations: CF diagnosis accepted 
c. Sweat value less than or equal to 60 mmol/L chloride: if the sweat value is less than or equal to 60 
mmol/L chloride, then at least 2 of these should be met: 
i. DNA Analysis/Genotyping – two identified disease causing CF mutations.  
ii. Transepithelial (Nasal) Potential Difference – study consistent with a diagnosis of CF.  
iii. Clinical Presentation – typical features of CF. 
d. Diagnosis reversal: if the patient’s CF diagnosis reversed during the year, identify the reason from the 
following options:  
i. DNA Analysis – unable to identify two disease causing CF mutations. 
ii. Transepithelial (Nasal) Potential Difference – study not consistent with a diagnosis of CF.  
iii. Repeat normal sweat testing – confirm with clinical team. 
Definitions for EFCSPR 
SWEAT TEST 
If a sweat test was not performed on a patient, record “not done”.  If a sweat test is “not done” then two known 
genotype mutations must be reported. 
i. Sweat Test: record the patient's sweat test.   
ii. Electrolytes: Chloride concentration measurement is the preferred analysis. 
iii. Chloride value: report the Chloride value in millimols per litre (mmol/L). If duplicate tests were completed 
on the same day, report the highest positive value.   
NOTE: The acceptable range for Chloride values is 1-160 mmol/L. Anyone who has a Chloride value above 160 
mmol/L must be re-tested. 
 
SPIROMETRY 
The purpose of recording data on spirometry values for the ECFS Patient Registry is to obtain standardised 
comparable data for comparison with other centres/countries and for use in specific epidemiological studies. 
Some of the conditions for this (see below) may not be met at every clinic visit for all patients. Therefore, for the 
purpose of the registry, only the spirometry tests fulfilling the criteria should be recorded/extracted for the ECFS 
Patient Registry. For all tests the spirometry should be performed according to the common ATS/ERS guidelines: 
(www.thoracic.org/statements/resources/pfet/PFT2.pdf). 
 
Furthermore for the values reported to the registry the following criteria should be met 
1. Pre-test 
a. date of birth, gender and height should be recorded for calculation of predicted values 
b. all recorded spirometry tests should be pre-bronchodilator* values 
i. short-acting bronchodilators: at least 4 hours pre-test 
ii. long-acting bronchodilators: at least 12 hours pre-test 
*This was decided according to the PortCF official definitions. 
2. Reported values 
a. for values reported to national registries or to centres and extracted to the ECFS Patient Registry, the 
value in litres of the highest available value of FEV1% of predicted (according to local references) of 
the year should be extracted 
b. each patient's FVC and FEV1 measurement must be reported in litres (L), with up to two places to the 
right of the decimal 
c. the FVC measurement must be greater than or equal to the FEV1 measurement 
d. for each reported spirometry value, the date of the test and the patient’s height at that date should 
be reported in order to perform the calculation of percent of predicted values 
e. only tests deemed valid according to ATS/ERS guidelines should be reported 
3. Calculation of percent of predicted values. A common set of reference values is used: 
Global Lung Function Initiative equations described by Quanjer PH et al. (Multi-ethnic reference values for 
spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–
1343). 
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In previous reports and presented in Appendix 3 of this report, page 126, calculations are based on the 
reference values:  
a. for male children 6-17 yrs and female children 6-15 yrs: Wang et al (1993) 
b. for male adults ≥ 18 yrs and females ≥ 16 yrs: Hankinson et al (1999) 
c. for children < 6 yrs no calculation of percent of predicted values will be performed because of lack of 
valid reference values 
 
The ECFSPR Definition Group considered the issue of race-specific reference values and decided not to do this 
calculation and not to record race for European patients. 
 
References: 
a) Miller et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338 
b) Miller et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153–161 
c) Cystic Fibrosis Foundation Patient Registry User’s Guide, Version 4.0. 2006 
d) Rosenfeld et al. Task Force to Evaluate Choice of Spirometric Reference Equations for the National Patient Registry: Summary and 
Recommendations. Cystic Fibrosis Foundation Registry Committee; 2005 
e) Hankinson JL, Odencrantz RJ, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respr Crit Care 
Med 1999;159:179-87 
f) Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88 
 
NUTRITION 
Measurements: weight and height are measured according to EuroCareCF guidelines 
a. weight: removal of outer clothing, shoes and socks 
b. height: without shoes and socks - stadiometer - top of head in contact with head board, slight 
pressure 
c. it should be the value at the day of the recorded FEV1 
z-scores for height, weight and BMI will be calculated using the CDC reference values [Kuczmarski et al 
(2002)] 
 
References: 
a) Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiss HC, Hesse V et al. Percentiles of body mass index in children and 
adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001; 149:807-818 
b) Lai H-C, Corey M, FitzSimmons S, Kosorok MR, Farrell M. Comparision of growth status of patients with cystic fibrosis between the 
United States and Canada. Am J Clin Nutr 1999; 69:531-538 
c) Public Use File BGS98, German National Health Interview and Examination Survey 1998, Robert-Koch-Institut, Berlin, Germany, 2000 
d) Wiedemann B, Paul KD, Stern M, Wagner TO, Hirche TO, on behalf of the German CFQA Group. Evaluation of body mass index 
percentiles for assessment of malnutrition in children with cystic fibrosis. Eur J Clin Nutr 2007; 61, 759-768 
e) Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 
2002; 11(246): 1-190 
 
DEFINITION OF CHRONIC INFECTION IN THE LOWER AIRWAYS 
1. Chronic PA infection should be defined by local physician according to modified Leeds criteriaa and/or anti-
pseudomonas antibodiesb. Patient should be defined as chronically infected if he/she fulfils the criteria now or 
has done so in recent years and the physician has no reason to think the status has changed 
a. modified Leeds criteria, chronic infection: >50% of the sputum samples, collected during the last 12 
months were positive.  At least 4 sputum samples during that period 
b. and/or significantly raised anti-pseudomonas antibodies according to local laboratories 
2. Chronic infection with other gram-negative bacteria should be recorded by the same criteria as above 
 
References: 
a) Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa in 
cystic fibrosis patients. J Cystic Fibrosis  
b) Proesmans M, Balinska-Miskiewiscz, Dupont L et al. Evaluating the ”Leeds criteria” for Pseudomonas aeruginosa infection in a cystic 
fibrosis centre. Eur Resp J 2006;27:937-943.  
c) Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European 
consensus. Eur Respir J 2000;16:749-767 
 
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) 
Diagnostic criteria: 
1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, 
change in pulmonary function, or increased sputum production) not attributable to another etiology. 
2. Total IgE > 500 IU/ml. 
3. Positive skin prick test for Aspergillus antigen (> 3 mm) or positive specific IgE for A. fumigatus. 
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4. Either: 
a. precipitins to A. fumigatus or in vitro demonstration of IgG antibody to A. fumigatus; 
b. or new or recent abnormalities on chest radiography (infiltrates or mucus plugging) or chest CT 
(characteristic changes) that have not cleared with antibiotics and standard physiotherapy. 
 
References: 
Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, 
Mastella G; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis--
state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S225-64. 
 
LIVER DISEASE 
We adopt the definitions for Liver Disease used by the UK Registry. These definitions discriminate patients with 
severe liver disease (with portal hypertension) from milder cases (cirrhosis without portal hypertension).  
Cirrhosis with Hypertension: scaring of the liver related to underlying CF, typically in a biliary pattern. 
Severe liver disease may include portal hypertension and/or hypersplenism.  
Cirrhosis without Hypertension: scaring of the liver relating to underlying CF. 
Liver disease without cirrhosis: this includes fatty liver or viral hepatitis but not biliary cirrhosis.  
 
PANCREATIC STATUS 
Definition: 
Stool fat (van de Kamer) > 4-5 g/d in young children, > 7g/d in children above 10 yrs and adults and/or faecal 
pancreatic elastase-1 < 200 ug/g. 
Two determinations are mandatory. Faecal fat excretion values of infants below 3 months are contradictory. 
Other than pancreatic causes of steatorrhoea must have been excluded. 
Pancreatic status will be assessed at the registry level, according to the following: 
Pancreatic insufficiency 
Faecal elastase <200 µg/g (twice) and Faecal fat high* (twice) 
Pancreatic sufficiency 
Faecal elastase ≥200 µg/g (twice) and Faecal fat normal* (twice) 
*according to definition above 
 
References: 
a) Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HGM, Robberecht E, Döring G.  Nutrition in patients with cystic 
fibrosis. A European consensus. J Cystic Fibrosis 2002; 1:51-75. 
b) Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA. Invited review: Indirect pancreatic function tests in 
children. J Pediatr Gastroenterol Nutr 2005; 40:107-114. 
 
  
 ECFSPR 
European Cystic Fibrosis Society Patient Registry 
 
Annual data report (year 2014) 
Version 02.2016 
 
 
  
126 
 
  
Appendix 3: Lung Function  
In this report we have introduced the computations based on the Global Lung Function Initiative equations 
described by Quanjer PH et al. In this appendix the graphs and tables of lung function are presented based 
on the reference populations and the equations described by Wang et al. for children and Hankinson et al. 
for adults (see Appendix 1, page 120, for full reference).  
Table 10.1 FEV1% of predicted: descriptive statistics, by country. Patients aged 6-17 years who 
have never had a lung transplant. 
Country N N Miss Mean 
 
(average 
FEV1%) 
Min 25th pctl 
 
(25% of 
patients have 
FEV1% below 
this value) 
Median 
 
(50% of 
patients have 
FEV1% below 
this value) 
75th pctl 
 
(75% of 
patients have 
FEV1% below 
this value) 
Max 
Austria 252 3 92.0 25.4 80.9 95.1 106.3 130.7 
Czech Republic 201 13 88.5 27.4 79.2 91.4 99.9 130.3 
Denmark 140 0 98.3 39.1 92.0 100.8 109.3 129.2 
France 2029 103 91.5 17.8 80.5 93.9 104.7 180.5 
Greece 130 2 99.7 21.4 89.9 101.6 112.1 149.4 
Hungary 207 16 78.2 16.7 67.2 80.8 93.8 129.2 
Ireland 358 12 90.7 25.7 80.0 93.2 103.3 151.9 
Israel 173 5 95.0 31.8 85.8 97.7 105.6 139.0 
Italy 1057 27 96.1 24.0 84.2 97.9 109.7 156.1 
Latvia 15 0 93.8 26.4 83.2 96.8 109.6 125.3 
Rep of Macedonia 51 2 96.5 30.7 85.1 98.3 114.1 130.3 
Rep of Moldova 22 2 77.7 22.0 66.1 79.9 96.6 108.0 
The Netherlands 410 10 90.2 29.1 78.5 91.1 103.7 135.6 
Portugal 103 8 84.4 23.9 69.4 88.3 103.5 130.4 
Romania 23 0 92.3 40.4 80.9 96.1 107.9 116.2 
Russian Federation 534 244 86.8 15.7 72.1 88.1 102.4 161.4 
Serbia 74 0 83.0 24.9 72.4 86.8 99.3 127.9 
Slovak Republic 76 0 86.0 26.2 77.2 89.7 97.7 121.4 
Slovenia 35 0 78.8 27.5 59.3 86.0 95.3 118.4 
Spain 517 18 92.3 28.0 81.7 95.1 105.4 139.5 
Sweden1 163 6 90.9 32.5 80.8 92.9 102.9 129.4 
Switzerland 226 4 91.8 26.9 80.8 93.1 104.4 134.2 
Ukraine 60 1 90.8 22.3 79.5 97.6 105.1 131.1 
United Kingdom2 2106 745 88.7 19.9 79.2 90.7 100.5 146.4 
 
1  Sweden reports FEV1 collected at the time of the annual review. 
2  United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
Note: For Lithuania coverage is 0% for children. 
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Table 10.1 shows some descriptive statistics for FEV1 in children, expressed as % of predicted. Note that 
patients who have had a lung transplant and children below 6 years of age have been excluded from the 
analyses. 
 
Figure 10.1  FEV1% of predicted: box-plot, by country and overall. Patients aged 6-17 years who have 
never had a lung transplant. 
 
 
Note:   Sweden reports FEV1 collected at the time of the annual review. 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note:  For Lithuania coverage is 0% for children. 
 
 
This box-plot is a graphic representation of the FEV1 in children, expressed as % of predicted detailed in 
table 10.1. For each country the dash (black line crossing the blue box) is the median, the black dot is the 
mean and the whiskers (vertical lines with a T-shaped end) are the minimum and the maximum.   
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Table 10.2 FEV1% of predicted: descriptive statistics, by country. Patients aged 18 years or older who 
have never had a lung transplant. 
Country N N Miss Mean 
 
(average 
FEV1%) 
Min 25th pctl 
 
(25% of 
patients have 
FEV1% below 
this value) 
Median 
 
(50% of 
patients have 
FEV1% below 
this value) 
75th pctl 
 
(75% of 
patients have 
FEV1% below 
this value) 
Max 
Austria 265 2 73.2 13.9 56.3 75.1 90.8 131.7 
Czech Republic 132 77 65.8 18.7 48.6 67.9 84.8 117.1 
Denmark 222 0 72.0 17.4 54.3 73.5 91.4 124.0 
France 2508 62 64.7 11.7 45.6 64.8 82.9 135.5 
Greece 185 0 64.0 16.1 42.0 63.8 85.9 114.9 
Hungary 162 7 69.6 14.6 49.6 70.6 94.6 108.9 
Ireland 329 19 63.9 15.4 45.1 63.7 81.4 126.3 
Israel 265 0 69.3 22.2 54.3 70.9 83.7 125.8 
Italy 1890 52 71.8 10.6 51.9 72.4 92.2 149.0 
Latvia <10 0 42.5 20.1 20.9 38.4 50.9 86.4 
Lithuania 12 0 59.7 21.4 28.7 60.8 87.6 95.0 
Rep of Macedonia 22 0 75.9 42.0 65.0 74.2 86.9 120.6 
Rep of Moldova 13 0 55.1 19.4 36.1 54.4 70.2 96.7 
The Netherlands 638 24 66.3 10.8 49.0 66.5 83.5 122.2 
Portugal 82 1 66.9 24.4 47.7 69.2 79.5 136.7 
Russian Federation 398 134 58.1 14.6 36.8 57.2 75.5 140.6 
Serbia 38 0 56.6 14.4 45.0 56.9 65.1 104.6 
Slovak Republic 112 0 68.9 17.1 49.7 72.1 88.7 119.6 
Slovenia 22 0 60.8 23.3 43.0 62.8 77.5 100.3 
Spain 474 13 66.4 20.1 48.3 67.0 84.1 123.0 
Sweden1 309 10 73.6 19.4 57.9 75.5 88.9 126.1 
Switzerland 303 0 63.9 12.3 46.8 61.6 81.7 113.9 
Ukraine 10 1 63.8 24.2 43.5 68.3 84.1 90.3 
United Kingdom2 3533 1261 67.9 13.0 49.6 68.5 85.7 150.7 
 
1  Sweden reports FEV1 collected at the time of the annual review. 
2  United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
Note: Romania has only one adult patient and is excluded from the table. 
 
This table shows some descriptive statistics for FEV1 in adults, expressed as % of predicted. Note that 
patients who have had a lung transplantation have been excluded from the analyses. 
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Figure 10.2 FEV1% of predicted: box-plot, by country and overall. Patients aged 18 years or older who 
have never had a lung transplant. 
 
 
Note:  Sweden reports FEV1 collected at the time of the annual review. 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: Romania has only one patient and is excluded from the graph. 
 
 
This box-plot is a graphic representation of the FEV1 in adults, expressed as % of predicted detailed in table 
10.2. For each country the dash (black line crossing the blue box) is the median, the black dot is the mean 
and the whiskers (vertical lines with a T-shaped end) are the minimum and the maximum.   
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Figure 10.3 Median FEV1% of predicted by age group and by country. Patients aged 6 years or older who 
have never had a lung transplant. 
 
 
Note: We excluded from the analyses those age groups wherein the number of patients was <10.  
Note: Not all the countries reported the best FEV1 value of the year (see tables 4.1 and 4.2). 
 
 
This graph shows the median FEV1% (the value that separates the highest and lowest half of the patients) 
by age group. Each country is represented by a dot (in blue) and the overall estimate is in red. The general 
pattern shows that the FEV1% slowly decreases until the age of 30-34, and then levels out. The patients in 
the oldest age groups are patients who survived, and may therefore represent the patients with less 
disease severity. There is considerable variability between countries. 
Table 10.3 FEV1% of predicted: descriptive statistics by age group (patients aged 6 years or older) who 
have never had a lung transplant. 
Age at FEV1 
measurement  
N N Miss Mean 
 
Min 25th pctl 
 
Median 
 
75th pctl 
 
Max 
6-9 3089 503 96.1 18.6 86.4 97.7 107.1 161.4 
10-14 3681 434 91.6 24.9 80.5 93.5 104.1 180.5 
15-19 3575 466 79.3 14.4 65.2 82.1 94.8 150.7 
20-24 3190 416 71.5 12.3 54.5 73.3 89.4 149.0 
25-29 2474 351 65.9 10.6 47.0 66.5 84.2 143.3 
30-34 1784 231 63.0 13.2 44.2 61.4 80.0 134.1 
35-39 1181 155 62.8 11.7 43.8 60.8 80.7 130.6 
40-44 777 130 63.0 13.9 44.1 60.9 80.9 138.5 
45+ 1142 198 64.2 10.8 44.7 61.4 82.4 137.3 
 
Note: Not every country reported the best FEV1 value of the year (see tables 4.1 and 4.2). 
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This table shows FEV1% by age group for the total data set. The median values reported in this table are 
shown as red dots in fig 10.3. 
Figure 10.4 Quartiles of FEV1% of predicted by age group and by country. Patients aged 6 years or 
older and who have never had a lung transplant. 
The figures below show the FEV1% in different age groups, separately for each country. The dot shows the 
median, and the whiskers show the 25th and 75th percentiles (the median, the 25th percentile and the 75th 
percentile are collectively named “quartiles”). In blue are the quartiles for the country, in red are the 
pooled quartiles computed on all other countries (i.e. excluding that country). We did not compute 
quartiles where the number of patients is <10 in an age group, so there are no blue dots for those age 
groups (the number of patients in each age group is shown below the horizontal axis). We therefore 
excluded Latvia and Lithuania from the graphs because none of the age groups had more than 10 patients. 
Quartiles of FEV1%: Austria Quartiles of FEV1%: Czech Republic 
  
 
Quartiles of FEV1%: Denmark 
 
Quartiles of FEV1%: France 
  
 
Quartiles of FEV1%: Greece 
 
Quartiles of FEV1%: Hungary 
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[figure 10.4 continued] 
Quartiles of FEV1%: Ireland Quartiles of FEV1%: Israel 
  
 
Quartiles of FEV1%: Italy 
 
Quartiles of FEV1%: Rep of Macedonia 
  
 
Quartiles of FEV1%: Rep of Moldova 
 
Quartiles of FEV1%: The Netherlands 
  
 
Quartiles of FEV1%: Portugal 
 
Quartiles of FEV1%: Romania 
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[figure 10.4 continued] 
Quartiles of FEV1%: Russian Federation Quartiles of FEV1%: Serbia 
  
 
Quartiles of FEV1%: Slovak Republic 
 
Quartiles of FEV1%: Slovenia 
  
 
Quartiles of FEV1%: Spain 
 
Quartiles of FEV1%: Sweden1 
  
 
Quartiles of FEV1%: Switzerland 
 
Quartiles of FEV1%: Ukraine 
  
 
Quartiles of FEV1%: United Kingdom2 
 
 
 
 
1  Sweden reports FEV1 collected at the time of the annual review. 
2  United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 annual 
report are restricted to those patients for whom prior annual surveys showed no prior lung transplants. 
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Figure 10.5  FEV1% of predicted according to severity group and age group, by country and overall.  
Patients aged 6-17 years who have never had a lung transplant. 
 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: For Lithuania coverage is 0% for children. 
 
 
Figures 10.5, 10.6 and 10.7 show the FEV1% by severity group, by country and overall. Patients with a 
FEV1% higher than 80% are generally considered to have mild lung disease, patients with FEV1% between 
80% and 40% moderate lung disease, and patients with FEV1 <40% severe lung disease. However, since a 
10 year old child with a lung function of 50% has considerably worse lung disease than a 50 year old patient 
with the same FEV1%, and the age distribution is not the same in all countries, we have chosen to present 
children (fig 10.5) and adults (fig 10.6 and 10.7) separately.  
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Figure 10.6 FEV1% of predicted according to severity group and age group, by country and overall. 
Patients aged 18-29 years who have never had a lung transplant. 
 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: Romania has only one patient and is excluded from the graph. 
 
 
Figure 10.7 FEV1% of predicted according to severity group and age group, by country and overall. 
Patients aged 30 years or older who have never had a lung transplant. 
 
 
Note: Not every country reported the best FEV1 value of the year: 
Sweden reports FEV1 collected at the time of the annual review; 
United Kingdom reports FEV1 collected at the time of the annual review. All analyses of FEV1 in the UK 2014 
annual report are restricted to those patients for whom prior annual surveys showed no prior lung 
transplants. 
Note: Romania has only one patient and is excluded from the graph. 
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